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 (i) 
 
ABSTRACT 
 
The project has focused on the preparation of several series of compounds designed as 
potential HIV-1 integrase inhibitors. Various 2-nitrobenzaldehydes have been reacted with 
two activated alkenes, methyl vinyl ketone (MVK) and methyl acrylate, under Baylis-Hillman 
conditions to afford α-methylene-β-hydroxylalkyl derivatives in moderate to excellent yields. 
The reactions were conducted using the tertiary amine catalysts, 1,4-diazabicyclo[2.2.2]octane 
(DABCO) or 3-hydroxyquinuclidine (3-HQ) with chloroform as solvent, and yields were 
optimised by varying the catalyst, reagent concentrations and the reaction time. Reductive 
cyclization of the Baylis-Hillman adducts via catalytic hydrogenation, using 10% palladium-
on-carbon catalyst in ethanol, afforded quinoline and quinoline N-oxide derivatives. In some 
cases “acyclic” reduction products were also isolated. 
 
Reaction of the Baylis-Hillman MVK adducts with HCl, has resulted in effective nucleophilic 
(SN’) displacement of the hydroxyl group to afford allylic chloride derivatives. Direct 
substitution of these chloro derivatives by secondary or primary amines, followed by catalytic 
hydrogenation gave quinoline derivatives containing a 3-aminomethyl substituent.  
 
The Baylis-Hillman ester adducts obtained from reaction with methyl acrylate were treated 
directly with various amines to give diastereomeric conjugate addition products. Reactions 
with piperazine gave N,N’-disubstituted piperazine products. The piperidine derivatives have 
been dehydrated to give cinnamate esters in moderate yields.  
 
The products, which have all been satisfactorily characterised by elemental (HRMS) and 
spectroscopic (1- and 2-D NMR) analysis, constitute a “library” of compounds for in silico 
and in vitro studies as potential HIV integrase inhibitors.  
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1. INTRODUCTION 
 
1.1 The Human Immunodeficiency Virus – Type 1 (HIV-1) 
 
The Human Immunodeficiency Virus (HIV) is a member of the lentivirus genus of the family 
Retroviridae and is categorised into two types, type 1 and type 2.1 The human retrovirus is 
associated with the disease, Acquired Immunodeficiency Syndrome (AIDS), in which HIV 
damages the immune system, leaving the body susceptible to infection from a wide range of 
bacteria, fungi and viruses. AIDS is one of the most serious and widespread diseases facing us 
and is an important challenge for chemotherapy in the 21st century. HIV-type 1 (HIV-1) is the 
predominant virus in the world, while the type 2 virus is restricted to countries in West 
Africa.1 The statistics indicate that, since the early 1980’s when the HIV virus was discovered 
and the AIDS name was defined, approximately 20 million people had died and 33 million 
people were infected with the disease in 2006.2    
 
The HIV virion (Figure 1) consists of an envelope, within which the corn-shaped 
proteinaceous capsid, surrounds the virus genome. The capsid and envelope contain proteins 
which aid entry into the cytoplasm of host cell.  
 
 
  
 
Fig. 1: The structure of an HIV virion (Reproduced with permission).3  
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The life cycle (i.e. the cycle of infection) of HIV-1 starts with the attachment of a 
glycoprotein (gp-120) protuberance of a free virion (Fig. 2) to a helper T-cell (also known as 
T-lymphocyte or CD4 cells) at a CD4+ receptor site.1, 4 The envelope of the virion and the 
membrane of the cell fuse together and the nucleocapsid within the virus enters the cell. 
Within the host cell the two single-stranded RNA genomes from the nucleocapsid are reverse-
transcribed into double-stranded proviral DNA which is then carried into the host cell nucleus 
and integrated with its chromosomal DNA (cDNA). The integrated viral DNA is transcribed 
into messenger RNA (mRNA) and carried out of the nucleus into the cytoplasm. Some of the 
mRNA becomes the genomes of progeny virions and some are translated into large protein 
molecules which are proteolysed into smaller functional components. After assembly of these 
viral proteins with the viral RNAs, enzymes, and some cell membranes, the new immature 
virion acquires its envelope by budding at the cell surface and leaves the infected host cell. 
The released viral particles become infectious after proteolytic mutation by the protease 
enzyme.5 
 
The genomic structure of the HIV-1 retrovirus is encoded with three types of genes: gag, pol 
and env (Fig. 3). The name gag comes from group-specific antigen; the protein encoded in 
this gene is highly conserved and forms the capsid of the retrovirion.6 The gag gene is 
followed by the pol gene; pol is short for polymerase (also known as Gag/Pol protein) which 
affords three functional enzymes: reverse transcriptase (RT), ribonuclease H (RNase H) and 
integrase (IN). The overlap region of the gag and pol gene is known as pro and it encodes a 
protease (PR) protein that is required for the processing of gag and pol. The protease is self-
cleaved from 5’-end of the pol precursor and it cleaves the RT, RNase H and IN apart from 
each other.4 The fourth gene, env, encodes the envelope glycoprotein present at the surface of 
the retrovirion. These four types of gene are present in all retroviruses and are always found in 
this order in the genome. There are various other genes present in the HIV genome, and they 
are known as auxiliary genes. These genes have many roles in transporting viral components 
within the cell, controlling viral gene expression, and modifying the body’s immune 
response.7 
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Figure 2: Cartoon of the HIV-1 life cycle: The orange circle is the HIV-1 virion ready to infect 
a healthy cell. The uninfected host cell is the large blue circle and the small blue circle inside it 
is the cell nucleus (reproduced with permission).8 
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Figure 3: Schematic representation of the genetic organization of the HIV-1 genome.4 
 
 
1.1.1   The enzymes as potential antiretroviral (ARV) targets  
 
Every enzyme in the HIV retrovirion has its own role in the HIV life cycle. It is therefore 
important to design and synthesise drugs that will stop the functioning of these enzymes and, 
as a consequence, stop the life cycle and hence stop the HIV infection. In order to do so, an 
enormous research effort has been concentrated on understanding the structure and function 
of the virus, the pathway of infection and the development of drug resistance. While attention 
is now is being given to inhibiting virion entry (i.e. fusion), the major potential targets in the 
HIV life cycle for designing antiviral drugs have been the reverse transcription, proteolysis 
and integration steps, and the enzymes responsible for each of these steps, RT, PR and IN, 
respectively. The application of ARV drugs in combination therapy, known as highly active 
antiretroviral therapy (HAART), has significantly reduced the mortality and morbidity rate of 
HIV/AIDS. Attention has also been given to dual inhibitors, i.e. single drugs inhibiting 
multiple steps in the HIV life cycle. A recent article describes attempts to synthesise an 
inhibitor for both RT and IN enzymes.9  
 
The pro gene encodes the protease enzyme (PR), which is responsible for the cleavage of the 
gag/pol polyproteins into structural and functional proteins essential for viral replication. The 
structure of the protease enzyme (Fig. 4) shows that the polypeptide exists in a homodimeric 
form,1 in which the active enzyme has a crystallographic two-fold (C2) rotational symmetry. 
Each monomeric chain supplies one aspartic acid (Asp-25 and Asp-25’) moiety in the active 
site between the two monomers. On “top” of the cavity are the two highly flexible β-hairpins 
(called “flaps”). Tόth et al.10 proposed that, when the polyprotein enters and docks into the 
 gag         
 p17 p24 p9 p7         
    pro pol  env   
LTR    PR RT RNase H IN  gp120 gp41  LTR 
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active site, hydrogen bonds form between the substrate flaps and the aspartic residues, and the 
protease conformation changes from semi-open to a closed conformation. As the 
conformation changes from open to closed, the two flaps extend over the polyprotein 
substrate and proteolysis occurs, cleaving the polyprotein. In fact, the enzyme functions as “a 
pair of molecular scissors”. To stop this from happening, inhibitors are required. The role of 
an inhibitor is to enter the active site, bind to the protease and block the active site such that 
the natural polyprotein substrates cannot enter.  
 
 
 
Fig. 4: A ribbon representation of HIV-1 PR; the yellow ribbons represent β-sheets, the white 
regions represent β-coils and the pink ribbons represent the alpha helices. A protease inhibitor 
(Ritonavir) is attached to the receptor cavity (active site). PDB code: 1HXW. 
 
 
There are currently a number of protease inhibitors (PRIs) available for clinical treatment, 
Ritonavir is a well known and popular inhibitor used in the treatment of HIV patients. It is a 
peptidic isostere that mimics the structure of the natural substrate and was approved for 
clinical use by the Food and Drug Administration (FDA) in March, 1996.11 
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The reverse transcriptase (RT) enzyme catalyses an essential step in the replication of HIV-
1, i.e. the synthesis of proviral DNA from retroviral RNA. RT exists in an asymmetric 
heterodimeric form composed of two subunits of identical sequences named p66 and p51.6 
The p66 subunit contains a triad of aspartic acid residues in the active site and exhibits DNA 
polymerase and RNase H activities, whereas the p51 subunit lacks these activities but 
provides structural support for the p66 subunit to upload onto the template primer.1, 4  
 
The reverse transcription process involves two activities; firstly, a DNA strand is 
manufactured from the RNA template of the virus (a process called DNA polymerizaition) to 
give hybrid double-stranded DNA and template RNA. The RNA strand is then destroyed by 
RNase H to give a so-called first-strand DNA or minus-strand DNA.6, 12 Secondly, the minus-
strand DNA acts as a template for DNA polymerization for the synthesis of the plus-strand 
DNA. This gives rise to the double-stranded proviral DNA suitable for integration (Section 
1.1.2). DNA synthesis takes place shortly after the virion enters the host cell and the proviral 
DNA can be detected within a few hours after infection. There are two categories of RT 
inhibitors (RTIs), nucleoside (NRTIs) and non-nucleoside (NNRTIs). The NRTIs are 
inhibitors that mimic the peptide structure of the major contacts between the p66 and p51 
subunits of RT to prevent heterodimer formation.2 The NNRTIs bind to the RT enzyme in a 
hydrophobic cavity adjacent to the polymerase catalytic site, where they are thought to inhibit 
chain elongation.13  
 
Another area of focus in the search for ARV drugs is inhibiting fusion of the HIV virion with 
the host cell and entrance of the virion into the cell. There are three steps in the entrance 
process: i) the HIV-1 gp-120 attaches to a CD4 cell; ii) gp-120 binds to the cell co-receptor 
(CCR5 or CXCR4); and iii) gp41-mediated membrane fusion.14-17 Each of these steps 
represents a unique drug target in designing ARV drugs and the general name for drugs 
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inhibiting these steps is entry inhibitors or, sometimes, fusion inhibitors. The gp-41 consists 
of three domains: an extracellular domain (ectodomain), a transmembrane domain and an 
intracellular domain (endodomain). The ectodomain contains three functional regions; the 
first region, fusion peptide (FP), consists of conserved hydrophobic residues that are essential 
for the penetration of the cell membrane. It has been confirmed that replacement of the 
conserved hydrophobic residues deflects gp41 fusion activity.18-22 The gp120 and gp41 
proteins change their conformation after the attachment to the CD4 cell and co-receptor, 
bringing the viral and cellular membranes into close proximity and leading to membrane 
fusion.16, 23 The first approved fusion inhibitor, Enfuvirtide (T20), has been shown to be 
effective in patients who fail to respond to RTIs and PRIs.24   
 
At present, there are five classes of drugs approved by the FDA for use with HIV patients, viz., 
nucleoside reverse transcriptase inhibitors (13), non-nucleoside reverse transcriptase 
inhibitors (4), protease inhibitors (11), fusion inhibitors (2) and an integrase inhibitor.25 
Despite the fact that there are many anti-HIV drugs approved by the FDA, the rate of 
morbidity and mortality continues world-wide, although recent data suggests that mortality 
rates may be levelling out or even dropping slightly.26 This indicates that clinical treatment of 
the HIV/AIDS infection is not sufficient to control viral replication and the formation of 
resistant strains. In order to keep the viral count of patients, who have developed resistance 
against RTIs and PRIs, as low as possible, new inhibitors need to be introduced. The HIV-1 
integrase enzyme offers an important target for intervention by such inhibitors.  
 
 
1.1.2     The integrase enzyme and inhibitors 
 
The HIV IN enzyme is endcoded within the pol gene and translated as a polyprotein; IN is 
released from the polyprotein by protease cleavage to give the 288 amino acid protein 
(32kDa). The IN polypeptide chain folds into three distinct domains: the N-terminal domain, 
the Centre core domain, and C-terminal domain (Fig. 5a-c).27 The complete 3-D structure of 
IN is not fully understood but it has been suggested that IN exists as a tetramer in human cells. 
The N-terminal domain (NTD) contains a catalytically important histidine-histidine-cystine-
cystine (HHCC) motif coordinated with a single zinc ion.27 Zinc binding is believed to 
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stabilise folding of the IN protein and to be involved in protein multimerization. The centre 
core domain (CCD) contains three catalytic acidic amino acids: aspartic acid (Asp) 64 (D), 
Asp 116 (D), and glutamic acid 152 (E), i.e. the DDE motif. Mutation of any of these residues 
abolishes IN enzymatic activity and prohibits virus replication. The motif forms an active site 
within IN and is coordinated with a divalent metal ion, usually Mg2+ or Mn2+, which is 
required for catalytic activity for DNA integration.7 The centre core domain is also known as 
the catalytic core domain as the role of the active site in this domain is to bind to the viral 
DNA. 
 
     
  
Figure 5: a) The catalytic core domain (CCD): three acidic residues D64, D116 and E152, 
(the DDE motif); b) N-terminal domain (NTD) with four residues, H12, H14, C40, and C43 
(green sticks), and a zinc atom (red sphere); c) C-terminal domain (CTD).28 d) crystal 
structure of CCD-NTD (PDB code: 1K6Y); and e) CCD-CTD (PDB code: 1EX4) 
(Reproduced with permission). 
 
(a)   (b)  (c) 
  (d)   (e) 
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The C-terminal domain (CTD) exhibits a very strong DNA binding activity and its role is to 
bind to the host DNA. All three domains have a dimeric structure and any alteration of the 
structure deactivates the activity of IN. While a crystal structure of the complete IN enzyme 
has yet to be determined, X-ray crystal structures of NTD with CCD and CTD with CCD 
have been determined (Fig. 5d and 5e).29 The IN enzyme binds to viral DNA, host DNA and 
the substrates during the catalytic process, and it is believed that the enzyme itself undergoes 
extensive conformational changes to permit favourable interactions.30 
 
 
HIV-1 integrase catalyses the integration of viral DNA with the host cell DNA in the cell 
nucleus, to give a complete DNA chain. While there are two main catalytic steps in the 
integration mechanism, there is a crucial step before the catalytic steps, viz., binding of IN to 
the viral DNA’s long terminal region (LTR) to give a stable viral DNA-IN complex.11 The 
first catalytic step, which then follows, is the 3’ processing (3’-P) step (Fig. 6), involving 
hydrolysis of dinucleotides from the 3’ end of the viral DNA LTR. The removal of the two 
nucleotides, the GT bases adjacent to highly conserved CA dinucleotides, occurs when a 
nucleophile (usually H2O) attacks the LTRs to expose a 3’ hydroxyl end (CA-3-OH). The 
removal takes place in the cytoplasm of the CD4+ T cell within the pre-integration complex 
(PIC). This complex contains host proteins and viral proteins, including IN, nucleocapsids, 
RT, and matrix and viral DNA.31 The HIV PIC enters the cell nucleus through a nuclear pore 
(nuclear translocation); however the mechanism of this translocation has not been fully 
elucidated.  
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Figure 6: The viral DNA and cDNA integration mechanism within the cell nucleus 
(reproduced with permission).32  
 
 
The second catalytic step, the strand transfer (ST) step, is a transesterification reaction and 
this takes place in the cell nucleus. The water molecule removes the TG dinucleotides from 
the 3’ end of the viral DNA. The 3’-OH group of the viral DNA acts as a nucleophile and 
attacks the 5’-phosphate end of the host DNA, leaving 5’-end of the viral DNA with an 
overhang of two nucleotides and a 5-base single-strand gap. The host cell DNA repair enzyme 
removes the overhanging nucleotides and repairs the single-strand gap to afford a complete 
integrated doubled-strand DNA.28 It was thought that although 3’ processing and strand 
transfer steps are very similar at a chemical level, the way the active site of IN interacts with 
the DNA substrate must differ for 3’ processing and strand transfer. 
 
Design and development of INIs began over 20 years ago and, while there are many potential 
INIs undergoing development, few are in clinical trials and there were no INIs available for 
HIV treatment before 12 October 2007, when the first integrase inhibitor, Raltegravir (brand 
name Isentress, Fig. 7), was approved by the FDA.11 This inhibitor was designed to inhibit the 
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strand transfer step and is manufactured by Merck.  
 
Lataillade and Kozal 31 have described various classes of pre-clinical and clinical drugs that 
inhibit different steps in the integration mechanism; there are pyrano-dipyrimidines (PDPs, 
preventing the viral DNA-IN binding process in vitro); styrylquinolines (SQLs); carbazole 
derivatives; β-diketo acids (DKAs) and their derivatives,33, 34 naphthyridines, fungal 
polyketides, and antimicrobial peptides (ST inhibitors); oxadiazoles (nuclear import 
inhibitors); and caffeine-related methylxanthines (host cell DNA repair protein inhibitors). 
Further classes of INIs have been summarised by Iyer et al.35 and these include chicoric acid, 
coumarins, aromatic sulfonamides, arylamides, naphthalene-based, curcumins,36 
salicyhydrazines, and many others (Fig. 8). The dual IN and RT inhibitor, V-165, inhibits 
viruses which show resistance against entry and RT inhibitors. This inhibitor targets both IN 
and RT steps; however it is believed that IN is the primary antiviral target for this inhibitor.32  
 
 
N
H
N
N
NHO
O
O
OH
F
O
N
N
 
Figure 7: Raltegravir (brand name: Isentress; or MK-0518 before approval) 
 
___________________________________________________________________  _     Introduction_ 
 
12 
 
  
OH
OH
O
O
O
OH
OO
OH
O
O
OH
O OO
OH
hydroxycoumarins
CAPE (L-chicoric acid derivitives)
F
NH
N
N
N
SO
O
O OH
L-870,810 (naphthyridine carboxamide)
OH
NH
O
NH
OH
O
salicylhydrazine
OH
OH
O
OH
O
O
OOH
O
OH
OH
OH
Lithospermic acid (natural product)
N
OH
OH
OH
HO2C
KHD16 (Styrylquinoline)
N
N
O
N
NSH
CH3 CH3
NO2
SH
V-165 (Dual inhibitor) quinolones
 
Figure 8: Classes of HIV-1 integrase inhibitors.  
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Quinolinonyl DKA derivatives are examples of bifunctional inhibitors, effective against both 
ST and 3’-P steps. Research has shown that the bi-DKA moiety may not be as efficient as the 
mono-DKA quinolinonyl systems. This hypothesis has been proved by Di Santo and his 
colleagues,26, 37 who synthesized and evaluated the antiviral activities of mono-DKA 
quinolinonyl compounds relative to bi-DKA quinolinonyl derivatives. 3-Acetyl-4(1H)-
quinolinones 2a-h, prepared by reacting aniline derivatives 1a-h with ethyl orthoformate and 
ethyl acetoacetate (Scheme 1), were alkylated with 4-fluorobenzyl bromide in alkaline 
medium (K2CO3) to give the N-substituted quinolones 3a-h. The acetyl derivatives 2a-h and 
3a-h undergo sodium ethoxide catalysed Claisen condensation with diethyl oxalate to give the 
ethyl esters 4a-h, which were hydrolysed with sodium hydroxide to afford the acid derivatives 
5a-h.26, 37   
 
 
 
NH2
i)
N
H
O
CH3
O
ii)
N
O
CH3
O
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N
O O
COOC2H5
OH
N
O O
COOH
OH
iv)
1a-h  
R1, R2, R3= H, F, and Cl iii) iii)
2a-h 3a-h
4a-h 
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4
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R3 R
3
 
Reagents and conditions: i) ethyl orthoformate, ethyl acetoacetate, Dowtherm A, 95-254°C, 8h;  ii) 4-
fluorobenzyl bromide, K2CO3, DMF, 100°C, 1h; iii) diethyl oxalate, C2H5ONa, THF, r.t., 2h; iv) 1M-
NaOH, THF/CH3OH, r.t., 40min. 
 
Scheme 1 
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The approved INI belongw to the DKA class, a very potent class of disintegration drugs 
which serve as lead compounds in the search for new INIs. There are numerous DKA ARV 
drugs in the different phases of clinical trials. Figure 9 show the structure of three DKA 
derivatives, which inhibit the strand transfer step in the HIV-1 integration mechanism. Full 
structures of IN enzymes with or without an inhibitor attached are not available, but in silico 
docking of 5-CITEP into the X-ray determined structure of the CCD led to the discovery of a 
new open space, the “trench”, which is adjacent to the active site and which 5-CITEP 
occupies.38 
 
 
O
CH3
N
OH
CH3
CH3
O OH
O
F
Cl
F
O O
OH
N N
NH
Cl
N
H
O O
N
NN
NH
S-1360 GS-91375-CITEP
 
Figure 9: DKA strand transfer inhibitors in clinical trials: the blue circles indicate the diketo 
acid moiety.  
 
 
Kawasuji et al.39, 40 have proposed a two-metal binding model for the HIV-IN inhibition 
mechanism, while Merchard et al.29 have suggested a similar mechanism, which is shown in 
Figure 10. The catalytic route is outlined with orange arrows and the inhibition route by the 
blue arrow. In stages A and B, the Mg2+ metal ion coordinates with the carboxylic groups of 
the acidic residues of the DDE catalytic triad of the enzyme within the active site. Each of the 
Mg2+ ions binds to a carboxylic oxygen from two different residues and to the phosphate 
oxygens of a coordinated viral DNA molecule. Water acts as a nucleophile attacking the 
phosphate ion of the viral DNA (stages B and C) to give a 3’-OH terminal fragment which 
then attacks the host DNA-Mg2+ complex at the phosphate centre (stage D) to give an 
integrated host DNA and viral DNA chain and metal-residue complex (stage E).  
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Figure 10: The two-metal binding HIV IN catalytic and inhibition mechanism, showing:- 
orange arrows (stages A to E) for the catalytic mechanism and a blue arrow (stage C to X) for 
IN inhibition; the viral DNA (in red) and the host DNA (in blue); the two metal cofactors as 
grey spheres; and the three IN enzyme amino acid residues (D116, D64, and E152 motif) of 
the DDE catalytic triad in the CCD active site in black (Reproduced with permission).40   
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Inhibition of the integration process occurs in stage X, when the inhibitor chelates with the 
metal ions, prohibiting coordination of host DNA and hence inhibiting integration. Discovery 
of the binding site within the catalytic domain of IN and formulation of the mechanism is the 
result of many years of research, using computer modelling, three-dimensional (3-D) database 
searching41, 42 and QSAR analysis.35 Numerous organic molecules were examined for potency 
as INIs, permitting a pharmacophore for INI drugs to be established. 
 
 
1.1.3   Styrylquinolines as HIV-1 integrase inhibitors 
 
The styrylquinolines (SQL) constitute a class of heterocyclic antiviral compounds which 
contain an ethylenic spacer connected to the quinoline moiety and an ancillary aromatic 
nucleus. The method typically used to generate SQLs involves a Perkin-type condensation 
which is slightly different to the usual Perkin condensation method. The usual method 
involves reaction between an aldehyde and an enolate anion derived from an ester, ketone, 
aldehyde or anhydride in the present of a base (sodium acetate or a tertiary amine) with or 
without solvent.43-45 Chandrasekhar et al.44 proposed a revised mechanism for the reaction 
(Scheme 2). Thus, reaction between benzaldehyde 6 and acetic anhydride 7 generate a gem-
diacetate 8 in high yield; an α-proton is then removed by the acetate ion, and cyclization 
affords intermediate 9. Electron delocalization activates the double bond of 9 to attack another 
benzaldehyde molecule 6 to afford intermediate 10; transfer of the acetyl group leads to 
intermediate 11 and elimination of benzaldehyde and acetate ion finally yields the cinnamic 
acid 13. 
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Scheme 2 
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Application of the Perkin-type condensation in the synthesis of styrylquinolines (e.g. 16) 
involves reaction of α-methylquinolines (e.g. 14) with a benzaldehyde (e.g. 15) in the absence 
of catalyst (Scheme 3) but typically in the presence of acetic anhydride.44 A proposed 
mechanism for this reaction is illustrated in Scheme 4. Thus, acetic anhydride is proposed to 
dissociate on reaction with the quinoline derivative 14; the released acetate anion then acts as 
a base removing a proton from the quinoline α-methyl group to generate the nucleophilic 
resonance-stabilised anion 18, which attacks the benzaldehyde 15. The acetate anion also 
attacks the carbonyl carbon of the N-acetyl group in intermediate 19 to regenerate acetic 
anhydride. Protonation and dehydration of the resulting alcohol 20 then affords SQL 16.   
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The SQL drugs act as HIV-1 integrase inhibitors, inhibiting the 3’ processing step by 
competing with the HIV’s LTR substrates, and to a lesser extent by inhibiting the nuclear 
translocation step. Researchers has explored numerous SQL derivatives with the aim of 
identifying the most active integrase inhibitors by monitoring their IC50 values.46-48 Based on 
the results, they have concluded that the substituents on the quinoline ring and ancillary 
aromatic ring are critical features for high antiviral activity. The styrylquinoline derivatives 
that exhibit high inhibition activity (i.e. low IC50 values) contain a COOH group at position 7 
and an OH group at position 8 of the quinoline moiety and a polyhydroxy ancillary aromatic 
ring.  (E)-8-Hydroxy-2-[2-(3,4,5-trihydroxyphenyl)ethenyl]-7-quinolinecarboxylic acid 16 
(Scheme 3) was found to be the most potent HIV-1 integrase inhibitor in in vitro experiments, 
blocking viral replication in cell cultures, with an IC50 value of 0.3µM without exhibiting 
cytotoxicity.46 (Other values have been reported over the years: 2.4µM in 200047 and 1.2µM 
in 200548) 
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Although, the first HIV-1 integrase inhibitor drug approved by FDA was a diketo acid, and β-
diketo acid derivatives appear to be the leading class of contenders as potential drugs, the 
styrylquinoline 16 also exhibits high anti-IN activity and shows a common sub-structure with 
the napthyridine carboxamide L-870810 (a potential INI in clinical trial) (Fig.11). These latter 
comounds exhibit a common hydrophilic domain with three heteroatoms (N or O, within the 
blue circle), permitting chelation with the two metal ions (generally Mg2+) in the IN CCD. 
 
Kawasuji et al.40 used computer modelling methods to explore the docking of 2-hydroxy-3-
heteroaryl acrylic acid derivatives (HHAAs) into the IN active site and identified two crucial 
active sites: a hydrophilic domain and a hydrophobic domain. The tautomeric hydrophilic 
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domain of the ligand (the blue-shaded motif; Scheme 5) permits chelation of the two metal 
ions via the enolate species, where X and Y represent heteroatoms that donate a lone-pair of 
electrons. The keto group is enolised and then ionised to give a negatively charged oxygen 
(enolate anion) enhancing the ability of the delocatlised system to coordinate to two metal 
ions at the same time. Application of the proposed two-metal ion binding mechanism (Fig 10) 
to the HHAA compounds is illustrated in Scheme 5 (in red). This model has also been used on 
the SQL compound 16 (in green), to illustrate the possible interaction between the enzyme 
and the SQL. 
 
metal ion
YOH
X
YO-
X
YO
X
YO
X
O
O
D 116 O
O
D 64
O O
E 152
O
O
O NN HHAA
O
O
D 116
O
O
D 64
O O
E 152
O
O
D 116
O O
D 64
O
O
E 152
N
O
OH
OH
OH
O
O
16
hydrophilic domain
 
Scheme 5 
___________________________________________________________________  _     Introduction_ 
 
20 
 
 
1.1.4  Aims of the present investigation 
 
The aim of this project has been to synthesise novel compounds that could act as HIV-1 
integrase inhibitors. More specifically, the research has included the following objectives: 
 
i. Use of Baylis-Hillman (BH) methodology to synthesise a series of α-methylene-β-
hydroxycarbonyl compounds from various o-nitrobenzaldehydes and methyl vinyl 
ketone (MVK) or methyl acrylate.   
ii. Nucleophilic substitution (SN’) on and aza-Michael addition to the BH-MVK adducts 
using various nucleophiles. 
iii. Reductive cyclization of the BH-MVK adducts and BH-MVK addition products to 
afford quinoline derivatives. 
iv. The formation of cinnamate esters from BH-methyl acrylate adducts as potential HIV-
1 integrase inhibitors. 
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2 DISCUSSION 
 
In the discussion, which follows, attention will given to the synthesis of Baylis-Hillman 
products (Section 2.1) and their reductive cyclization to quinoline derivatives (Section 2.2), 
The 2-methyl quinolines obtained using MVK have been subjected to Perkin-type 
condensation to afford styrylquinolines (Section 2.4). The Baylis-Hillman adducts obtained 
using MVK and methyl acrylate have been elaborated further by:- i) substitution reactions 
(Section 2.5); ii) nucleophilic addition (Section 2.6) and; iii) dehydration to give cinnamate 
esters (Section 2.7). Attention has also been given to the synthesis of bis-styrylpyridine 
derivatives (Section 2.8). 
 
 
2.1 Synthesis of Baylis-Hillman products  
 
The Baylis-Hillman reaction is so named after the scientists A. B. Baylis and M. E. D. 
Hillman who, in 1972, patented the use of tertiary amines as effective catalysts for the 
coupling of ethyl acrylate or acrylonitrile with acetaldehyde.49 Morita50 had previously 
reported similar transformations using phosphine catalysts and, hence, the reaction is also 
known as the Morita-Baylis-Hillman (MBH) reaction. The Baylis-Hillman (BH) reaction has 
been used extensively to couple activated alkenes with aldehydes and other suitable 
electrophiles, and application of the reaction in the synthesis of various heterocyclic systems 
has been one of the main foci in our research group. The Baylis-Hillman reaction is a useful 
method for forming a new carbon-carbon single bond between an aldehyde 21 and, for 
example, an α,β-unsaturated carboxyl derivative 22 to yield an α-methylene-β-
hydroxycarbonyl derivative 24. This reaction requires an unhindered nucleophilic tertiary 
amine catalyst 23, most commonly,: 1,4-diazabicyclo[2.2.2]octane (DABCO) 23a, 4-
dimethylaminopyridine (DMAP) 23b, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 23c, 3-
hydroxyquinuclidine (3-HQ) 23d and imidazole 23e (Scheme 6).  
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The aldehydes chosen for the BH reactions in this study were the 2-nitrobenzaldehydes 25a-k, 
while methyl vinyl ketone (MVK) and methyl acrylate were used as the activated alkenes. 
The different reactions undertaken and the corresponding products and isolated yields are 
summarised in Scheme 7 and Table 1. The reactions were run at atmospheric pressure and 
room temperature. The reaction times ranged from 2 to 30 days with chloroform being used as 
the solvent and DABCO 23a as the catalyst. At the end of each reaction, the solvent was 
removed under reduced pressure and the residue chromatographed, by flash chromatography, 
to give the desired product. For the MVK adducts the DABCO was removed by washing a 
solution of the reaction mixture in EtOAc with 10% hydrochloric acid. The yields of the 
Baylis-Hillman products 26a-k varied considerably but, in a number of cases, the yields were 
very good (Table 1). In general, the Baylis Hillman ester adducts 26g-k were obtained in 
higher yields and within shorter experimental times (2 to 7 days) than the MVK derivatives 
26a-f (7 to 30 days). 
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Table 1: Yields of Baylis-Hillman products 26a-k (Scheme 7). 
 R1 R2 R3 R4 R5 % Yield 
a H H H H CH3 45 
b H OH H H CH3 89 
c H OCH2O H CH3 27 
d H OCH3 OCH3 H CH3 58a 
e H H H OCH3 CH3 40 
f H Cl H H CH3 88 
g H H H H OCH3 96 
h H H H OCH3 OCH3 98 
i Cl H H H OCH3 91 
j H OCH2O H OCH3 54 
k H H NO2 H OCH3 96 
a
 Crude yield. 
 
The mechanism of the BH reaction has been studied by several research groups,51 including 
our own;52, 53 the currently accepted details are illustrated in Scheme 8. The catalytic cycle 
begins by conjugate addition of DABCO 23a to the activated alkene 22, generating a 
zwitterionic intermediate 27. The adol-type addition of intermediate 27 to 25 leads to the 
enolate anion 28, which undergoes proton transfer to afford the resonance-stabilised anion 29. 
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Elimination of DABCO via an E1CB process then gives the β-hydroxy-α-methylene product 
26.  
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The Baylis-Hillman products 26a-k were fully characterised by NMR, IR and high- and low-
resolution MS analysis. There are a number of significant features one should look for in the 
1H NMR spectrum of a BH adduct which indicate formation of the product, viz., i) two 
singlets at ca. 6 ppm corresponding to the two vinylic protons and ii) a singlet due to the 4-
methine proton in the same region. The 1H NMR spectrum of adduct 26b (Fig. 12) shows a 
methyl singlet at 2.30ppm and the three significant signals at 5.60 and 6.16 ppm (vinylic 
protons) and at 6.19 ppm (4-methine proton). The vinylic protons are diastereotopic and give 
rise to two discrete signals. The signals between 6.50 ppm and 8 ppm are due to the three 
aromatic protons, while the two hydroxyl protons resonate as a doublet at 5.81 and a broad 
singlet at 10.90 ppm.  
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Figure 12: 400MHz 1H NMR spectrum of 4-hydroxy-3-methylene-4-(5-hydroxy-2-
nitrophenyl)butan-2-one 26b in CDCl3. 
 
  
Of the products obtained from reactions with MVK, the Baylis-Hillman MVK adduct 26b, 
was isolated after 30 days in the highest percentage yield (89%). Initially the starting material 
25b was immiscible with CHCl3 but, after 8 days, the solid dissolved. The reaction was 
monitored using thin layer chromatography (TLC) and, after 30 days, TLC analysis indicated 
complete consumption of the reactant 25b. The expected 11 signals for the adduct (26b) were 
observed in the 13C NMR spectrum (Fig. 13) with the methyl carbon signal at 26.0 ppm and 
carbonyl signal at 198.0 ppm. The DEPT 135 NMR spectrum (Fig. 14) shows the presence of 
the vinylic methylene carbon signal at 125.0 ppm and the 4-methine carbon signal at 64.9 
ppm..  A clear correlation between the 4-hydroxy and 4-methine protons (circled) is evident in 
the COSY NMR spectrum (Fig. 15) confirming the coupling observed for their respective 
signals in the 1H NMR spectrum.  
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Figure 13: 100MHz 1H NMR spectrum of 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-
methylenebutan-2-one 26b in DMSO-d6. 
 
 
 
Figure 14: DEPT 135 NMR spectrum of 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-
methylenebutan-2-one 26b in DMSO-d6. 
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Figure 15: 400MHz COSY NMR spectrum of 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-
methylenebutan-2-one 26b in DMSO-d6. 
 
 
To synthesise compounds 26a-f, the reactants, nitrobenzaldehyde, MVK and DABCO, were 
used in the ratio 1:1.5:0.5.54 In some cases, additional MVK and DABCO were added if the 
TLC analysis indicated that the reaction was no longer proceeding and a large amount of 
starting material was still present. The yield reported in Table 1 for compound 26d is the 
crude yield before any form of purification. It was observed that if the crude mixture was left 
for a period of time, reversion to the 2-nitrobenzaldehyde 25d and MVK precursors 
occurred.55 This reversion was evident from 1H NMR spectra, in which the intensities of the 
characteristic vinylic and 4-methine proton signals began to decrease over time. This 
phenomenon was also observed with the BH adduct 26c. 
 
It had been reported in a previous study in our group52, 53  that BH reactions using MVK may 
not only give the desired β-hydroxy-α-methylene product (e.g., 26a-k), but also the methyl 
vinyl ketone dimer 30 and the bis-MVK adduct 31 (Scheme 9). Similar observations have 
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been reported by Shi et al..56, 57 The MVK dimer and bis-MVK adduct were, in fact, obtained 
in some cases in the present study. Figure 16 illustrates the 1H NMR spectrum of the MVK 
dimer 30, revealing the two methyl singlets at 2.10 and 2.30ppm, the methylene multiplets at 
ca. 2.54 ppm and the vinylic signals at 5.80 and 5.99 ppm. The 1H NMR spectrum of a 
mixture of the MVK dimer 30e and the bis-MVK adduct 31e is illustrated in Figure 17. The 
signals arising from the bis-MVK adduct 31e are visible at 2.22 and 2.56 ppm for the 4-
methylene protons, ca. 3.9 ppm for the OMe and 8-OH protons, and at 3.09 and 4.66 ppm for 
the 5- and 6-methine protons, respectively.   
 
 
H
O
NO2
R1
R2
R3
R4
+
OH
NO2
R5
OR1
R2
R3
R4
DABCO
CHCl3 +
CH3 CH3
O O
DABCO
O
CH3
OH
NO2
R5
OR1
R2
R3
R4 O CH3
25c-e 22i 26c-e
30
31
O
25        R=
c           4,5-OCH2O
d           4,5-dimethoxy
e           3-OMe
 
Scheme 9 
 
____________________________________________________________________   _      Discussion_ 
29 
 
  
Figure 16: 400MHz 1H NMR spectrum of the MVK dimer (3-methyleneheptan-2,6-dione) 30 
in CDCl3. 
 
 
 
Figure 17: 400MHz 1H NMR spectrum of a mixture of the MVK dimer 30 and 5-acetyl-6-
hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 31e in CDCl3. 
 
2xCH3 
CH3 1
2
3
4
5
6
CH37
O
CH2
O
C=CH2 4 and 5-CH2 
1 '
2 '
6 '
3 '
5 '
4 '
6
5
OH
NO2
4
CH3
O
O
3
2
CH2
O CH31CH3
OCH3 and 
OH 
6-H
 
5-H
 
4-Hb
 
4-Ha
 
____________________________________________________________________   _      Discussion_ 
30 
 
The Baylis-Hillman reaction was the first step in the proposed synthesis of the styrylquinoline 
derivatives and, therefore, it was crucial to optimise the yields of the BH adducts. This was 
attempted by varying the catalyst, the solvent, the reactant concentrations and reaction times. 
The first approach was to change the solvent from chloroform to dichloromethane and to cool 
the mixture (ca. 0°C) during the addition of reactants to give cleaner products.58 The reaction 
was carried out using 2-nitrobenzaldehyde 25a and MVK 22i in the presence of DABCO, and 
terminated after 7 days. This increased the yield of the reaction from 45% to 60% and 
purification of the product was much simpler.  
 
Scheme 10 outlines three further approaches to optimising the reaction conditions. Firstly, 
DMAP was used as catalyst and DMF as solvent; Shi et al.56 had reported that the reaction of 
o-nitrobenzaldehyde with DMAP as the Lewis base took place in 20 hours in DMF to give the 
BH adduct 26a in 83% yield. The same reaction conditions were therefore adopted using the 
o-nitrobenzaldehydes 25a and 25c. The reactions were terminated after 20 hours, but the 
product yields (5-23%, Table 2) were not as promising.  
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Table 2: Yield of of Baylis-Hillman products 26a,c,d. 
R Method Product Yield/% 
H i 26a 23 
4,5-OCH2O- i 26c 5 
H ii 26a 22 
H iii 26a 43 
4,5-diOCH3 Iii 26d 27 
 
 
The second approach involved following the method reported by Luo et al.,59 who used 
aqueous THF and 1M aq. NaHCO3 as the reaction medium and imidazole as catalyst, to 
accelerate the reaction and produce relatively high yields (ca. 88%). Davies et al.60 have 
found that water can play a crucial role in the acceleration of the Baylis-Hillman reactions. 
However, application of this method gave the product 26a in only 23% yield. The last 
variation examined was the Morita-Baylis-Hillman reaction where the catalyst used was a 
phosphine rather than a tertiary amine. The reaction in THF was co-catalysed by 
triphenylphosphine and nitrophenol, and was terminated after 20 hours to afford products 26a 
and 26d in 27 % and 43% yield, respectively. This method also gave a relatively low yield 
compared to the 98% yield reported by Shi.61  
 
Other attempts to increase the yields involved altering the catalyst from DABCO to 3-HQ 23d. 
It was found that reactions conducted using 3-HQ proceeded more quickly than when using 
DABCO. The Baylis-Hillman products 26b,c,f-k were prepared again under the same reaction 
conditions as before, but replacing DABCO with 3-HQ.51, 62 It was observed that the reactions 
were completed 1 to 2 days faster than when DABCO was used, but the products were 
isolated in similar yields to previous preparations using DABCO (see Table 1).  
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2.2 Synthesis of quinoline derivatives 
 
Many compounds possessing a quinoline moiety are known to exhibit high biological 
activities against malarial, fungal, bacterial and protozoan infections.63-66 These compounds 
include chloroquine, as an antimalarial drug, and 8-hydroxyquinoline and its derivatives as 
antifungal drugs. The method adopted for the synthesis of quinoline derivatives in our 
research group has involved the reductive cyclization of o-nitrobenzaldehyde derived BH 
products. The reaction takes place in a cascade of three steps, hydrogenation, cyclization and 
dehydration. 
 
The Baylis-Hillman adducts were first dissolved in 50mL of ethanol, the air inside the 
reaction vessel was extracted under reduced pressure and argon introduced into the vessel –
the process being repeated three times before the addition of the 10% palladium-on-carbon 
catalyst. Thereafter, the vessel was flushed out three times with argon as before, and, finally, 
the hydrogen gas was introduced into the vessel. The hydrogenation reaction may proceed via 
two different pathways. The reaction outlined in Scheme 11, shows that the nitro group of the 
substrate 26 is reduced to the amino derivative 32, the nitrogen lone pair electron may then 
attack the methylene carbon (path I) or the carbonyl carbon (path II) to give 
tetrahydroquinolines 33 or the tetrahedral intermediates 34, respectively. In the systems 32 
examined here, cyclization was found to be regioselective, with path II being favoured.53 
Once formed, the intermediate 34 may undergo nucleophilic acyl substitution to products 36, 
37 and 38 when the substrate is an ester (R1=OMe) or nucleophilic addition to products 35 
when R1 is ketone (R1=Me). 
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One of the aims of the project was to synthesise quinoline derivatives and, hence, the reaction 
pathway to product 35 needed to be followed. The Baylis-Hillman products 26a and 26b were 
used in this study. The reaction was terminated after 3 hours stirring under H2 and the solvent 
was removed under reduced pressure. Following the procedure reported by Pakade52 CH2Cl2 
was added to the crude mixture; however, a brown precipitate formed as the residue mixed 
with CH2Cl2. The precipitate was filtered off and both the solid and filtrate were analysed by 
NMR spectroscopy (see Figures 18 and 19).  
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Figure 18: 400MHz 1H NMR spectrum of the isolated solid, comprising a mixture of 6-
hydroxy-2,3-dimethylquinoline 35b and 6-hydroxy-2,3-dimethylquinoline-N-oxide 39b, in 
DMSO-d6. 
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The 1H NMR spectrum of the solid showed the presence of two products with overlapping 
signals in the aromatic region, while the 13C NMR spectrum gave a much clearer picture. In 
the latter spectrum (Fig. 19), for example, the signal at 108.3 ppm is accompanied by a 
adjacent but less intense signal at 107.4 ppm. This phenomenon is evident across the spectrum 
with each major signal being accompanied by a minor signal corresponding to the major and 
minor products. Isolation of the two products was not considered practicable, since TLC 
analysis showed the presence of only a single spot and attempts to separate the two products 
by changing the elution solvent were unsuccessful. It was concluded that the two products 
comprising the solid must have similar polarity, the two products were presumed to be 6-
hydroxy-2,3-dimethylquinoline 35b and the corresponding quinoline N-oxide 39b. This 
assumption was supported by low resolution MS analysis which indicated the presence of 
molecular ions for both 35b (m/z 173 g.mol-1, Fig. 20) and 39b (m/z 189g.mol-1).  
 
 
 
Figure 19: 100MHz 13C NMR spectrum of the isolated solid, comprising a mixture of 6-
hydroxy-2,3-dimethylquinoline 35b and 6-hydroxy-2,3-dimethylquinoline-N-oxide 39b, in 
DMSO-d6. 
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Figure 20: GCQ low resolution mass spectrum of the isolated solid, comprising a mixture of 
6-hydroxy-2,3-dimethylquinoline 35b and 6-hydroxy-2,3-dimethylquinoline-N-oxide 39b. 
 
 
 
It was previously observed 52, 53 that the 2,3-dimethylquinoline derivatives 35 and 39 were not 
the only products obtained in this reaction, but that the “acyclic” derivatives 40 could also be 
isolated. This was reported by Klaas53 and Pakade52. The formation of N-oxide 39 is attributed 
to the incomplete reduction prior to cyclization.  Klaas53 and Pakade52, working in our group 
had shown that the N-oxides isolated in these reactions can be readily reduced to the 
corresponding quinolines using phosphorus tribromide in DMF.  
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The hydrogenation reaction proved to be less straightforward than expected, since the reaction 
produced more than one product, and therefore an alternative method was examined. 
Basavaiah et al. 67 reported a one-pot reaction for the synthesis of quinolines from Baylis-
Hillman products by making use of Fe powder and acetic acid. Applying this method to 
substrate 26c, the reaction mixture was refluxed for 30 minutes to afford the quinoline 
derivative 44c, as a white solid in 20% isolated yield. The reaction sequence is outlined in 
Scheme 13. Thus, the nitro compound 26c was reduced to the aniline derivative 41c before 
cyclization to intermediate 42c; acetic acid then attacked the methylene carbon in an acid-
catalysted SN1 process (illustrated by 43b) to generate quinoline product 44c.  
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The 1H NMR spectrum of compound 44c (Fig. 21) indicated there were two methyl signals at 
2.11 and 2.65 ppm, two methylene signals at 5.20 and 6.07 ppm, and three aromatic proton 
signals (7-8 ppm). This clearly indicated that the 3-acetoxymethyl-2-methyl-6,7-
(methylenedioxy)quinoline 44c had been formed. Removal of the acetyl group can be 
achieved by methanolysis using K2CO3 in methanol.67 
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Figure 21: 400MHz 1H NMR spectrum of 3-acetoxymethyl-2-methyl-6,7-(methylenedioxy)-
quinoline 44c in CDCl3. 
 
 
2.3 Perkin-type condensation of quinolines to styrylquinolines  
 
The final step in the synthesis of styrylquinoline compounds as potential HIV-1 integrase 
inhibitors was the Perkin-type condensation reaction, the mechanism of which is outlined in 
Scheme 4 (p.21, Section 1.1.3). A trial reaction was carried out using quinaldine (2-
methylquinoline) 45, as a model system, and benzaldehyde 46 (Scheme 14) in the presence of 
acetic anhydride, which acted as both a catalyst (see Scheme 2, p.19) and a solvent. The 
mixture was refluxed for 16 hours. A black crystal, which slowly formed during the reaction, 
was removed and recrystalized from chloroform-hexane to afford (E)-2-styrylquinoline 47 as 
a yellow powder in 30% isolated yield. The 1H NMR spectrum of compound 47 (Fig. 22B) 
showed no evidence of the methyl signal at 2.70 ppm which is characteristic of the quinaldine 
spectrum (Fig. 22A). The spectrum of 2-styrylquinoline 47 was expanded to facilitate 
assignment of all the expected (Fig. 23).  
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N CH3
+
O
H
N
45 46 47
Acetic anhydride
Reflux, 16h
 
Scheme 14 
 
 
Figure 22: 400MHz 1H NMR spectrum of A) quinaldine 45 and B) (E)-2-styrylquinoline 47 
in CDCl3. 
 
 
The Perkin-type condensation is an effective method for the synthesis of styryl-like 
compounds. However, the disadvantages of this method are the long reaction time (ranging 
from 12 hours to 4 days), low yield and excess of reagent (benzaldehyde) required.52, 53, 65, 66, 68-
70
 Microwave assisted organic synthesis (MAOS) is an alternative to the traditional approach. 
Musiol and his colleagues64-66 were able to synthesize styrylquinoline using a microwave-
assisted reaction in which the substituted quinaldine and aldehyde derivatives were irradiated 
in a microwave oven for 4 to 6 minutes at different power levels and temperatures, which 
N CH3
N
A) 
B) 
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were determined based on the reagents used. This method apparently solved the problems 
experienced using normal reflux. 
 
 
 
Figure 23: 100MHz 13C NMR spectrum of (E)-2-styrylquinoline 47 in CDCl3, expanded to 
facilitate assignment. 
 
 
The same reagents detailed in Scheme 14 were used for the microwave reaction. Acetic 
anhydride was mixed with the reactants 45 and 46 in a reaction vessel, which was inserted 
into the microwave reactor and the mixture subjected to the reaction conditions listed in Table 
3. The results showed a much higher yield (60-80%) and TLC analysis of the mixtures from 
all three reactions indicated the absence of competition product. Optimization of the 
microwave reaction, including power and temperature settings, and its application in the 
preparation of the styrylquinolines targeted in the present study will be the focus of future 
work. 
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Table 3: Microwave reaction conditions for the reaction of compounds 45 and 46.  
 Power (W) Temperature (°C) Time (min) 
1) 150 120 5 
2) 200 150 7 
3) 300 178 5 
 
 
The synthesis of quinoline derivatives was not as simple as expected, therefore alternative 
pathways to the styrylquinoline were considered, including condensation of Baylis-Hillman 
products 26a (R=H) and 26c (R=4,5-OCH2O-) with benzaldehyde 46 to afford 48a,c followed 
by cyclization to afford styrylquinoline derivatives 49a,c (Scheme 15). This reaction was 
conducted using both the conventional thermal reaction system and a microwave-assisted 
reaction. However, the using both approaches were disappointing with formation of none of 
the desired product 49a,c.  
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2.4 Substitution reactions of Baylis-Hillman products  
 
The vinylic group in the 2-nitrophenyl Baylis-Hillman products 26 may undergo two different 
reactions, viz., conjugate addition or nuclecophilic substitution with rearrangement (SN’) 
(Scheme 16) depending on the R2 group. When R2 was methyl, the substrate 26 was first 
reacted with HCl. The chlorinated SN1 product 52 could then be reacted with nitrogen 
nucleophiles, via direct SN’ reaction, and then cyclised to give quinoline derivatives 54. With 
the ester (R2=OMe), however, conjugate addition by nitrogen nucleophilies, followed by 
dehydration afforded the corresponding prodcuts 51. 
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Scheme 16 
 
Thus, treatment of the Baylis-Hillman products 26b,c,f with HCl (generated from acetyl 
chloride in ethanol, Scheme 17), which attacked the vinylic carbon, gave 3-chloromethyl-4-
(2-nitrophenyl)but-3-en-2-one 52 (Scheme 17). This is an exothermic reaction and, therefore, 
the reaction vessel was placed on ice to avoid overheating. The reaction vessel was open to 
the atmosphere, with a condenser attached to prevent loss of the mixture in the event of over-
heating. The chloromethyl ketones 52b,c,f were isolated in extremely high yield. 3-
Chloromethyl-4-(4,5-methylene-2-nitrophenyl)but-3-en-2-one 52c was obtained as a clean 
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product  without any purification, in quantitative yield (Table 4). The vinylic proton signals 
characteristic of the substrate 26c were absent in the 1H NMR spectrum of the product 52c 
(Fig. 24), confirming the transformation. However, the HRMS analyses with ESI 
(electrospray ionization) and EI (electron ionization) has failed to detect the molecular ion of 
the products 52b,c,f. This warrants further exploration.  
 
OOH
NO2
O
NO2 Cl
26b,c,f 52b,c,f
R1
R2
R1
R2
 
Scheme 17 
 
 
 Table 4: Chlorinated Baylis-Hillman products 52b,c,f . 
 R1
 
R2 Yield (%) 
52b OH H 94 
52c OCH2O 100 
52f Cl H 94 
 
Acetyl Chloride 
EtOH, 0°C 
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Figure 24: 400MHz 1H NMR spectrum of 3-chloromethyl-4-(4,5-methylene-2-
nitrophenyl)but-3-en-2-one 52c in CDCl3. 
 
 
 
2.5 Conjugate addition reactions of Baylis-Hillman products with amine 
nucleophiles  
 
The nucleophilic addition of primary or secondary amines to the Baylis-Hillman products 
may be achieved via two different routes (Scheme 18). When R2 is methyl, direct addition of 
an amine to the Baylis-Hillman products 26 is not possible,55 and must be preceded by 
substitution with chloride, as described above. Direct conjugate addition of the nucleophile to 
the vinylic β-carbon is only possible when R2 is an OMe. The primary and secondary amines 
selected for the methyl ester Baylis-Hillman products 26g-k were piperidine 56, piperazine 60 
and L-proline methyl ester hydrochloride 57, as shown in Scheme 18 and 19. The reactions 
with piperidine and piperazine were carried in THF, whereas methanol (containing 
triethylamine to neutralise the hydrochloride salt) was used as the solvent for the L-proline 
methyl ester hydrochloride reaction. The reaction mixtures were stirred for 3 to 7 days to give, 
as diastereoisomeric mixtures, the products listed in Table 5.  
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Scheme 18 
 
 
Table 5: Percentage yields of the compounds 58g-59g (Scheme 18).  
 
 
 
 
 
 
 
 
    a As a mixture of four diastereomers. 
    b Reaction not performed. 
 
 
In the NMR spectra of the diastereoisomeric mixture 58g – 59g, the 3-methine signals at ca. 
5 – 6 ppm were diagnostic of the desired products - a separate signal for each diastereomer. 
Integration of these signals permitted the ratio of two diastereomers to be determined in each 
case. In the 1H NMR spectrum of 58g (Fig. 25), the two doublets at 5.30 and 5.79 ppm 
exhibited coupling constants of 8.8Hz and 4.0Hz, for the major and minor diastereomers, 
respectively, which their relative integrals indicated a diastereomeric ratio of 2:1. In the 13C 
NMR spectrum (Fig. 26) the total number of carbon signals was almost double the total 
 R 58 59 
g H 74 54a 
h 3-OMe 76 b 
i 6-Cl 61 b 
j 4,5-OCH2O- 95 b 
k 4-NO2 57 b 
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number of carbons expected for either diastereomer and almost every major signal was 
accompanied by a minor signal. The DEPT 135 spectrum (Fig. 27) showed four pairs of 
methine signals which corresponds to the four aromatic methine carbons and one pair of 
methylene signals corresponding to C-10. The C-11/15 and C-12/14 methylene signals for 
each diastereomeric pair overlap at 26.3 and 55.1 ppm, respectively. The 10-methylene 
carbon signals, however, are well separated. 
 
 
 
Figure 25: 400MHz 1H NMR spectrum of a mixture of diastereomers of methyl 3-hydroxy-3-
(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58g in CDCl3. 
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Figure 26: 100MHz 13C NMR spectrum of a mixture of diastereomers of methyl 3-hydroxy-
3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58g in CDCl3. 
 
 
 
Figure 27: 100MHz DEPT 135 NMR spectrum of a mixture of diastereomers of methyl 3-
hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58g in CDCl3. 
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The piperidine derivatives 61g-k were obtained in moderate to good yields, but the piperazine 
reactions had an unwanted outcome (see Table 6). Reaction of 1eq. of the Baylis-Hillman 
adducts 26g-k with 1.5eq. of piperazine 60 was expected to form the mono-substituted methyl 
piperizinyl-propanoate esters 61g-k. The 1H NMR spectrum (Fig. 28), while indicating the 
presence of a contaminant, appeared to be compatible with such a conclusion. However, the 
results from HRMS indicated otherwise. The MS spectrum (Fig. 29) contains a peak at m/z 
324 which corresponds to M+1 for the mono-substituted products 61g (R=H) as well as a base 
peak at m/z 560 which corresponds to the disubstituted piperazine 62g (Scheme 19). It was 
unclear whether both of the products were present or only the disubstituted 62g, and a DOSY 
(Diffusion-Ordered Spectroscopy) experiment was run to confirm the results. 
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Table 6: Percentage yield of compounds 62g-k (Scheme 19). 
 
 
 
 
 
 
 
 
a
 The product was not found in any of the fractions collected. 
 
 
 
 
Figure 28: 400MHz 1H NMR spectrum of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(2-
nitrophenyl)]piperazine 62g in CDCl3. 
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Figure 29: HRMS spectrum of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(2-nitrophenyl)]-
piperazine 62g using electrospray ionization plus source. 
 
 
The DOSY experiment is a pseudo-chromatographic 2-D NMR experiment where the pulsed 
field gradient (PFG) and the deuterated solvent serve as the “mobile phase”. The separation 
occurs when two or more compounds in a mixture show a difference in size and shape, which 
affects their mobility and their diffusion coefficients.71-74 Figure 30 is the original data from 
the DOSY experiment, where the 1H NMR spectrum of 61g was run over number of scans (y-
axis) with increments in the field gradient intensity. The 2-D DOSY spectrum (Fig. 31) 
indicated that the solute was a single product and, not a mixture of mono- and di-substituted 
piperazines. All the signal peaks in the blue circles in the spectrum have the same diffusion 
coefficients; the signals outside the blue circles correspond to the deuterated chloroform and 
impurities in the CDCl3. The DOSY experiment was only conducted on 62g and 62j and, in 
both cases, the results indicated the formation of the bis-substituted piperazines. The HRMS 
data for the products of the reaction of piperazine with Baylis-Hillman adducts 26g-i, which 
were all obtained in very low yield (≤6%), indicated the presence of the corresponding 
disubstituted piperazines 62h, 62i, and 62k.  
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Figure 30: DOSY experiment scans of  N,N’-bis[2-carbomethoxy-3-hydroxy-3-(2-
nitrophenyl)]piperazine 62g with chemical shift on x-axis and scan number on the y-axis. 
 
 
   
Figure 31: 2-D DOSY spectrum of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(2-
nitrophenyl)]piperazine 62g in CDCl3. 
 
Chemical shift 
Sc
an
 
n
u
m
be
r 
____________________________________________________________________   _      Discussion_ 
52 
 
In the conjugate addition of L-proline methyl ester hydrochloride to Baylis-Hillman derivative 
26g, a base was needed to free the nucleophilic amino group from the hydrochloride salt. Two 
different bases were examined, proton sponge and triethylamine. The reaction with proton 
sponge was deemed unsuccessful after stirring for 14 days. However, chromatography of the 
crude product (with triethylamine in the mobile phase), revealed the presence of four 
stereoisomers (59g1-4), which were characterized using NMR spectroscopy and elemental 
analysis. 
 
 
The chlorinated Baylis-Hillman products 52b,c,f were also treated with various amines (56, 
57, 63, and 64) as illustrated in Scheme 20. The reactions were conducted in either THF or 
methanol (with triethylamine to neutralise the hydrochloride salts). The reactions were 
terminated after 3-7 days and the crude products chromatographed to afford the expected 
products in moderate to excellent yields (Table 7). In these reactions, it seems that direct (SN) 
substitution proceeds smoothly and in the 1H NMR spectrum of compound 65b, for example, 
(Fig. 32) the allylic methylene signal appears as a singlet at 3.09 ppm; the vinylic 4-methine 
proton was the most deshielded giving rise to a signal at 7.76 ppm.  
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Table 7: Yields of the nucleophilic substitution products 65-68.  
a
 Reaction not performed.  
b
 Reaction attempted but no product obtained after chromatography. 
 
 R 65 66 67 68 
b 5-OH 79 a a 20 
c 4,5-OCH2O- 86 57 52 a 
f 5-Cl 90 a 36 b 
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Figure 32: 400MHz 1H NMR spectrum of 4-(4,5-methylenedioxy-2-nitrophenyl)-
3[(piperidin-1-yl)methyl]but-3-en-2-one 65c in CDCl3.  
 
 
2.6 Reductive cyclization of Baylis-Hillman  products to quinoline 
derivatives 
 
The products 65c-67c, derived from BH adducts 26c, were treated with 10% Pd-C and H2 for 
1.5 hours in ethanol afford 2-methylquinoline derivatives 69c-71c. 2-Methyl-6,7-
methylenedioxy-3-[(piperidin-1-yl)methyl]quinoline 69c was isolated in 12% yield, after 
purification, while products 70c-71c were obtained in crude yields of 18-23% (Scheme 21). 
The most deshielded signal in the 1H NMR spectrum of 65c (Fig. 32) at 7.78 ppm corresponds 
to the 4-H nucleus whereas in the spectrum of 69c it is the 8-H nucleus at 8.08 ppm (Fig. 33). 
In the 13C NMR spectrum (Fig. 34), the carbonyl signal at 199.9 ppm (in the spectrum of the 
substrate 65c) has disappeared, indicating that the cyclization has occurred. However, for the 
synthesis of 70c and 71c, both reactions gives a complex mixture and no purification were 
done due to time constraints.  
 
11-CH2 
CH3 3
11
4
NO2
5
68
7
9
10
N
2
CH31
O
O
O 13
12
14
15
16
4-CH 
OCH2O 
12,16-
CH2 
13,14,15-
CH2 
____________________________________________________________________   _      Discussion_ 
55 
 
10% Pd-C/H2
EtOH
69c  12%
N CH3
NO
O
NO2
CH3
O
N
O
O
NO2
CH3
O
N
O
O
CH3
O
O
NO2
CH3
O
NH
O
CH3
H
O
O
O
OH
65c
66c
67c
N CH3
NO
O
O
O
CH3
70c   18%
71c  23%
N CH3
NHO
O
O
CH3
H
O
OH
 
Scheme 21 
 
 
 
Figure 33: 400MHz 1H NMR spectrum of 2-methyl-6,7-methylenedioxy-3-[(piperidin-1-
yl)methyl] quinoline 69c in CDCl3. 
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Figure 34: 100MHz 13C NMR spectrum of 2-methyl-6,7-methylenedioxy-3-[(piperidin-1-
yl)methyl] quinoline 69c in CDCl3. 
 
 
 
2.7 Dehydration of Baylis-Hillman products to afford cinnamate esters  
 
The second approach to potential HIV-1 integrase inhibitor was explored, namely, the 
synthesis of cinnamate esters from BH derivatives. Sai et al. 75 have published a paper on a 
stereoselective method to synthesise (E)- and (Z)-α-substituted cinnamates using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as a dehydrating agent. The reaction proceeds via 
an E2 elimination reaction of syn- and anti-α-substituted-β-hydroxyesters. They reported that 
syn-α-substituted-β-hydroxyesters will undergo E2 elimination reaction to give a mixture of 
(E)- and (Z)-α-substituted cinnamates whereas anti-α-substituted-β-hydroxyesters react 
stereoselectively to give, (E)-α-substituted cinnamates (Z:E, 1:99).75 A possible explanation 
for this phenomenon is that the α-proton of the β-hydroxyester is too acidic for E2 elimination 
to compete with E1cB elimination. The most effective reaction conditions, concluded Shi et 
al., involved 1eq. of β-hydroxyester, 2eq. of EDC and 0.1eq. of CuCl2 reacting in refluxing 
toluene for 2 hours. Applying this method, dehydration of the methyl 3-hydroxy-3-(2-
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nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate esters 58g,h,j  was effected by refluxing in 
toluene with EDC for 4 hours to afford the diastereoisomeric mixture (E)-72 and (Z)-73 in 8-
50% yield (Scheme 22, Table 8). In the 1H NMR spectrum of 72g and 73g (Fig. 33) the 
signals corresponding to 3-vinylic proton at 5.53 and 5.77 ppm and 2-methine proton at 3.16 
and 3.31 ppm have disappeared and new 3-vinylic proton signals appeared at 7.26 and 7.97 
ppm. In the reaction of 58g,h,j with EDC the (E)-cinnamate esters 72 are the main products 
(72g:73g :: 1:2,72h:73h :: 1:7, and 72j:73j :: 1:4).  
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Table 8: Yields of dehydrated diastereomeric compounds 72-73g,h,j (Scheme 22). 
 R= % Yields 
g H 50 
h 2-OMe 16 
j 4,5-OCH2O- 8 
 
 
The mechanism for the dehydration reaction of the syn- and anti-α-substituted-β-
hydroxyesters (anti-74 and syn-75) is outlined in Scheme 23. Formation of intermediates 75i 
and 75ii result from reacting EDC and CuCl2 with anti-74 and syn-75. The dimethyl amino 
group in EDC facilitates the deprotonation step. The intermediates 75i and 75ii eliminate 
EDC to give the products (E)-72 and (Z)-72, respectively. 
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Figure 35: 400MHz 1H NMR spectrum of methyl (2E)-3-(2-nitrophenyl)-2[(piperidin-1-
yl)methyl]-prop-2-enoate 72g and methyl (2Z)-3-(2-nitrophenyl)-2[(piperidin-1-yl)methyl]-
prop-2-enoate 73g in CDCl3. 
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2.8 Conclusion 
 
The reaction of a range of 2-nitrobenzaldehydes with methyl vinyl ketone and methyl acrylate 
has successfully led to the isolation of the corresponding Baylis-Hillman products in moderate 
to excellent yields. Other by-products were also formed in some reactions, including the 
MVK dimer and bis-MVK products. Reductive cyclization of the Baylis-Hillman adducts via 
catalytic hydrogenation was found to afford the expected quinoline derivatives as the major 
products with the quinoline N-oxides being isolated as the minor products. Another method of 
cyclization to afford quinolines was examined, viz., one-pot reductive cyclization using 
Fe/acetic acid, but this approach afforded the required products in low yield. Thermal Perkin-
type condensation reactions of 2-methylquinolines with benzaldehyde in the presence of 
acetic anhydride proved to be time-consuming and, therefore, microwave-assisted reactions 
were explored, but the results were disappointing.  
 
Conjugate addition of secondary or primary amines to the Baylis-Hillman methyl acrylate 
adducts produced mixtures of stereoisomers, while the reaction with piperazine resulted in the 
formation of N,N’-disubstituted products instead of the expected mono-substituted analogues. 
Cinnamate esters have been identified as potential HIV-1 integrase inhibitors and, in this 
study, the mono-substituted amino derivatives were dehydrated using EDC and CuCl2 in 
refluxing to toluene to access several novel cinnamate ester derivatives. SN’ displacement of 
the hydroxyl group in the MVK-derived Baylis-Hillman adducts by HCl, followed by direct 
(SN) substitution of chloride by various amino compounds proceeded smoothly and excellent 
yields were obtained for both reactions. However, attempts to reductively cyclize these 
products were not successful.  
 
Many of the compounds prepared in this study are new, and future work is expected to 
involve computer modelling and biological assays to explore their antiretroviral activities.  
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3. EXPERIMENTAL  
 
3.1 General 
 
NMR spectra were recorded on Bruker AMX 400MHz or 600MHz spectrometers in CDCl3 or 
DMSO-d6. Spectra run in CDCl3 were calibrated using the residual CHCl3 signal at 7.25 ppm 
for 1H and the CDCl3 77.00 ppm for 13C; spectra run in DMSO-d6 were calibrated using the 
residual DMSO signals at 2.5 ppm for 1H and the DMSO-d6 signal at 39.4 ppm for 13C. 
Infrared spectra were recorded on a Perkin Elmer FT-IR spectrum 2000 spectrometer, using 
nujol mulls or KBr discs. Melting points were determined using a Reichert 281313 hot-stage 
apparatus and are uncorrected 
 
Low-resolution mass spectra were carried out on a Finnigan-Mat GCQ mass spectrometer 
using the electron ionisation (EI) mode, and the high-resolution mass spectra on a Waters API 
Q-TOF Ultima instrument with electrospray ionisation (ESI+) source (Stellenbosch 
University; Central Analytical Facility). Microwave reactions were conducted using a CEM 
Focused MicrowaveTM Discover reactor.  
 
Chemical reagents were used as supplied by Sigma-Aldrich, without further purification. 
Flash chromatography was carried out using Separations silica gel 60 (particle sizes 0.040-
0.063mm) and preparative layer chromatography was conducted using Merck silica gel 60 
PF254. Thin layer chromatography (TLC) was conducted using Merck aluminium plates, pre-
coated with silica gel 60 F254.  
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3.2 Preparation of Baylis-Hillman products 
 
General Method: To a solution of 2-nitrobenzaldehyde (1eq.) and methyl vinyl ketone (or 
methyl acrylate) (1.5eq.) in CHCl3, was added DABCO (or 3-HQ) (0.05eq.), and the reaction 
mixture was stirred in a stoppered flask at room temperature for periods which varied 
according to the 2-nitrobenzaldehyde used in the reaction. The solvent and excess MVK (or 
methyl acrylate) were removed in vacuo and the crude product was purified by flash 
chromatography or preparative layer chromatography. 
 
4-Hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 26a 
3
CH2
4
NO2
1 '
2 '4 '
3 '
5 '
6 ' 2
CH31
OOH
   
The general procedure was followed, using 2-nitrobenzaldehyde (4.98g, 33.0mmol), methyl 
vinyl ketone (4.1mL, 50mmol), DABCO (0.19g, 1.7mmol) in CHCl3 (1mL) and the mixture 
was stirred for 7 days. The crude product was purified by flash chromatography on silica gel 
[elution with hexane-EtOAc (3:1)] to afford, as red-brown crystals, 4-hydroxy-3-methylene-4-
(2-nitrophenyl)butan-2-one 26a (3.28g, 45%), m.p. 78-80°C (lit.52 80-81°C); νmax (KBr)/cm-1 
3345 (OH) and 1665 (C=O); δH (400MHz; CDCl3) 2.35 (3H, s, CH3), 3.54 (1H, br d, J=3.2Hz, 
OH), 5.58 and 6.16 (2H, 2xs, C=CH2), 6.20 (1H, d, J=3.2Hz, CHOH), 7.44 (1H, t, J=7.8Hz, 
4’-H), 7.63 (1H, t, J=7.6Hz, 5’-H), 7.76 (1H, d, J=8Hz, 6’-H), and 7.94 (1H, d, J=8Hz, 3’-H); 
δC (100MHz; CDCl3) 26.0 (C-1), 67.4 (C-4), 124.6 (C-3’), 126.5 (C=CH2), 128.5 (C-4’), 
128.8 (C-6’), 133.5 (C-5’), 136.4 (C-1’), 147.9 (C-2’), 148.8 (C=CH2) and 199.8 (C=O); m/z 
222 (M+1, 40%) and 161 (100%). 
 
4-Hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-methylenebutan-2-one 26b 
3
CH2
4
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1 '
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OOH
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The general procedure was followed, using 5-hydroxy-2-nitrobenzaldehyde (3.0g, 18mmol), 
methyl vinyl ketone (4.3mL, 52mmol), DABCO (0.10g, 0.90mmol) in CHCl3 (15mL) and 
stirred for 34 days. The crude product was purified by flash chromatography on silica gel 
[elution with hexane-EtOAc (1:1)] to afford, as a yellow solid, 4-hydroxy-4-(5-hydroxy-2-
nitrophenyl)-3-methylenebutan-2-one 26b (4.2g, 89%), m.p. 150-152°C (lit.52 131-133°C); 
νmax (KBr)/cm-1 3358 (OH) and 1626 (C=O); δH (400MHz; DMSO-d6) 2.30 (3H, s, CH3), 5.60 
and 6.16 (2H, 2xs, C=CH2), 5.81 (1H, d, J=5.0Hz, OH), 6.19 (1H, d, J=4.8Hz, CHOH), 6.81 
(1H, dd, J=8.8Hz and 2.8Hz, 4’-H), 7.13 (1H, d, J=2Hz, 6’-H), 7.94 (1H, d, J=6.4Hz, 3’-H) 
and 10.85 (1H, br s, 5’-OH); δC (100MHz; DMSO-d6) 26.0 (C-1), 64.7 (C-4), 114.4 (C-4’), 
114.9 (C-6’), 125.0 (C=CH2), 127.7 (C-3’), 138.9 (C-2’), 142.3 (C-1’), 150.4 (C=CH2), 162.3 
(C-5’) and 19.0 (C=O); m/z 238 (M+1, 4%) and 191 (100%) 
 
 
4-Hydroxy-3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one 26c 
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The general procedure was followed, using 3,4-methylenedioxy-6-nitrobenzaldehyde (2.0g, 
12mmol), methyl vinyl ketone (1.30mL, 15.6mmol), DABCO (0.06g, 0.5mmol) in CHCl3 
(4mL) and stirred for 7 days. The crude product was purified by flash chromatography on 
silica gel [elution with hexane-EtOAc-CHCl3 (1:1:3)] to afford, as a yellow solid, 4-hydroxy-
3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one 26c (0.9g, 27%), m.p. 98-99 
(lit.53 100-103°C); νmax (KBr)/cm-1 3466 (OH) and 1624 (C=O); δH (400MHz, CDCl3) 2.37 
(3H, s, CH3), 3.54 (1H, br s, OH), 5.75 and 6.12 (2H, 2xs, C=CH2), 6.11 (2H, s, OCH2O), 
6.18 (1H, s, CHOH), 7.19 (1H, s, 6’-H) and 7.51 (1H, s, 3’-H); δC (100MHz, CDCl3) 26.0 (C-
1), 67.4 (C-4), 103.0 (OCH2O), 105.5 (C-3’), 107.7 (C-6’), 126.1 (C=CH2), 134.2 (C-1’), 
141.8 (C-2’), 147.2(C-7’), 149.1 (C=CH2), 152.29 (C-4’) and 199.49 (C=O); m/z 266 (M+1, 
14%) and 188 (100%). 
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4-(4,5-Dimethoxy-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 26d 
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The general procedure was followed, using 4,5-dimethoxy-2-nitrobenzaldehyde (2.0g, 
8.9mmol), methyl vinyl ketone (1.5mL, 13mmol), DABCO (0.11g, 0.90mmol) in CHCl3 
(4mL) and stirred for 7 days. The crude product was purified by flash chromatography on 
silica gel [elution with hexane-EtOAc-CHCl3 (1:1:3)] to afford, as a yellow-brown oil, 4-(4,5-
dimethoxy-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 26d (1.4g, 89%) (lit.52 
yellowish-brown oil); νmax (KBr)/cm-1 3449 (OH) and 1712 (C=O);  δH (400MHz; CDCl3) 
2.37 (3H, s, CH3), 3.40 (1H, br s, OH), 3.93 and 4.11 (6H, 2xs, 4’- and 5’-OCH3), 5.57 and 
6.04 (2H, 2xs, C=CH2), 6.30 (1H, s, CHOH), 7.30 (1H, s, 6’-H) and 7.62 (1H, s, 3’-H); δC 
(100MHz; CDCl3) 26.1 (C-1), 56.8 and 56.8 (2xOCH3), 68.2 (C-4), 108.5 (C-6’), 110.5 (C-
3’), 126.1 (C=CH2), 134.8 (C-1’), 145.0 (C-2’), 147.9 (C-5’), 149.6 (C-4’), 153.7 (C=CH2) 
and 200.5 (C=O); m/z 281 (M+1, 12%), and 43 (100%). 
 
4-Hydroxy-4-(3-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 26e and 5-acetyl-6-
hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 31e 
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The general procedure was followed, using 3-methoxy-2-nitrobenzaldehyde (1.2g, 6.9mmol), 
methyl vinyl ketone (0.86mL, 10mmol), DABCO (38mg, 0.34mmol) and CHCl3 (2mL). The 
crude product was purified by flash chromatography on silica gel [elution with hexane-EtOAc 
(1.5:1)] to afford, 
Faction 1: as a brown oil, 4-hydroxy-4-(3-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 
26e (0.69g, 40%) (lit.52 reddish-brown oil); νmax (KBr)/cm-1 3449 (OH) and 1712 (C=O); δH 
(400MHz; CDCl3) 2.34 (3H, s, CO.CH3), 2.86 (1H, br s, OH), 3.87 (3H, s, ArOCH3), 5.64 
(1H, d, J=1.2Hz, 4-H), 5.95 and 6.22 (2H, 2xs, C=CH2), 6.99 (1H, d, J=8.4Hz, ArH), 7.11 
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(1H, d, J=8Hz, ArH), and 7.42 (1H, t, J=8Hz, 5’-H); δC (100MHz; CDCl3) 26.0 (C-1), 56.3 
(OCH3), 67.8 (C-4), 111.9 (C-4’), 119.2 (C-6’), 127.8 (C=CH2), 131.1 (C-5’), 134.3 (C-1’), 
139.9 (C-2’), 147.4 (C=CH2), 150.6 (C-3’) and 199.7 (C=O); m/z 205 (M+-NO2, 10%) and 
125 (100%). 
 
Fraction 2: as a reddish-brown oil, 5-acetyl-6-hydroxy-6-(3-methoxy-2-nitrophenyl)-3-
methylene-2-hexanone 31e (10%); νmax (KBr)/cm-1 3433 (OH) and 1624 (C=O); δH (400MHz; 
CDCl3) 2.08 and 2.33 (6H, 2xs, 1- and 8-CH3), 2.22 and 2.56 (2H, 2xm, 5-CH2), 3.09 (1H, m, 
3-H), 3.86 (4H, m, OCH3 and OH), 4.66 (1H, m, 4-H), 5.86 and 6.06 (2H, 2 x s, C=CH2), 6.93 
(1H, d, J=8Hz, 6’-H), 7.09 (1H, d, J=8Hz, 4’-H) and 7.41 (1H, t, , J=8Hz, 5’-H); δC 
(100MHz; CDCl3) 25.6 (C-1), 40.0 (C-4), 31.9 (C-8), 55.1 (C-6), 56.5 (OCH3), 69.6 (C-5), 
111.9 (C5’), 119.0 (C-6’), 128.8 (C=CH2), 131.3 (C-4’), 135.4 (C-2’), 140.2 (C-1’), 145.0 (C-
3’), 150.5 (C-3), 211.5 and 213.4 (2xC=O).  
 
4-(5-Chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 26f 
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The general procedure was followed, using 5-chloro-2-nitrobenzaldehyde (5.5g, 2.7mmol), 
methyl vinyl ketone (0.33mL, 4.1mmol), DABCO (16mg, 0.14mmol) in CHCl3 (0.6mL) and 
stirred for 6 days. The crude product was purified by flash chromatography on silica gel 
[elution with hexane-EtOAc (3:1)] to afford, as a red solid, 4-(5-chloro-2-nitrophenyl)-4-
hydroxy-3-methylenebutan-2-one 26f (0.61g, 88%), m.p. 75-78°C (lit.52 72-74°C); νmax 
(KBr)/cm-1 3449 (OH) and 1692 (C=O); δH (400MHz; CDCl3) 2.37 (3H, s, CH3), 3.54 (1H, br 
s, CHOH), 5.76 and 6.16 (2H, 2xs, C=CH2), 6.23 (1H, s, CHOH), 7.42 (1H, dd, J= 2.0 and 
8.4Hz, 4’-H), 7.77 (1H, d, J=2.4Hz, 6’-H) and 7.95 (1H, d, J=8.8Hz, 3’-H); δC (100MHz; 
CDCl3) 26.0 (C-1), 67.1 (C-4), 126.2 (C-6’), 126.7 (C=CH2), 128.6 (C-4’), 129.1 (C-3’), 
138.7 (C-1’), 140.3 (C-5’), 146.0 (C-2’), 148.5 (C=CH2) and 199.7 (C=O); m/z 256 [M+1 
(35Cl), 0.98%] and 178 (100%). 
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Methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 26g 
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The general procedure was followed, using 2-nitrobenzaldehyde (3.0g, 20mmol), methyl 
acrylate (2.7mL, 30mmol), DABCO (0.12g, 1.1mmol) and CHCl3 (0.6mL). The reaction 
mixture was stirred for 2 days and the crude product was purified by flash chromatography on 
silica gel [elution with hexane-EtOAc (3:1)] to afford, as a pale-green oil which slowly 
crystallized to a pale-green solid, methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 
26g (4.6g, 96%), m.p. 36-38°C (lit.76 cited as oil); νmax (KBr)/cm-1 3471 (OH) and 1710 
(C=O); δH (400MHz; CDCl3) 3.49 (1H, br s, OH), 3.71 (3H, s, OCH3), 5.71 and 6.34 (2H, 2xs, 
C=CH2), 6.18 (1H, s, CHOH), 6.45 (1H, t, J= 8Hz, 4’-H), 7.63 (1H, t, J=7.6Hz, 5’-H), 7.73 
(1H, d, J=7.6Hz, 6’-H) and 7.92 (1H, d, J=8Hz, 3’-H); δC (100MHz; CDCl3) 52.2 (OCH3), 
67.6 (C-3), 124.54 (C-3’), 126.5 (C=CH2), 128.7 (C-4’), 128.9 (C-6’), 122.4 (C-5’), 136.1 (C-
1’), 140.7 (C=CH2), 128.3 (C-2’) and 166.4 (C=O); m/z 238 (M+1, 10%) and 78 (100%). 
 
Methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-methylenepropanoate 26h 
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The general procedure was followed, using 3-methoxy-2-nitrobenzaldehyde (3.0g, 17mmol), 
methyl acrylate (2.2mL, 25mmol), DABCO (1.1g, 0.83mmol) and CHCl3 (1mL). The reaction 
mixture was stirred for 3 days and the crude product was purified by flash chromatography on 
silica gel [elution with hexane-EtOAc (1:1)] to afford, as a brown solid, methyl 3-hydroxy-3-
(3-methoxy-2-nitrophenyl)-2-methylenepropanoate 26h (4.33g, 98%), m.p. 112-114°C (lit.76 
108-109°C); νmax (KBr)/cm-1 3485 (OH) and 1706 (C=O); δH (400MHz; CDCl3) 3.30 (1H, br 
s, OH), 3.69 (3H, s, CO2CH3), 3.88 (3H, s, OCH3), 5.63 (1H, s, CHOH), 5.86 and 6.40 (2H, 
2xs, C=CH2), 6.98 (1H, d, J=8.4Hz, 4’-H), 7.08 (1H, d, J=7.6Hz, 6’-H) and 7.41 (1H, t, J 
=8Hz, 5’-H); δC (100MHz; CDCl3) 52.1 (CO2CH3), 56.5 (OCH3), 68.2 (C-3), 112.2 (C-4’), 
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119.3 (C-6’), 127.3 (C=CH2), 131.3 (C-5’), 134.3 (C-1’), 139.6 (C=CH2), 140.4 (C-2’), 150.8 
(C-3’) and 166.1 (C=O); m/z 268 (M+1, 4.4%) and 221 (100%). 
 
Methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 26i 
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The general procedure was followed, using 6-chloro-2-nitrobenzaldehyde (0.10g, 0.54mmol), 
methyl acrylate (0.07mL, 0.8mmol), DABCO (3.6mg, 0.03mmol) and CHCl3 (0.3mL), the 
reaction being completed in 5 days. The crude product was purified by flash chromatography 
on silica gel [elution with hexane-EtOAc (3:1)] to afford, as a yellowish-brown semi-solid, 
methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 26i (134mg, 91%) (lit.76 
cited as solid, m.p. 99-101°C); νmax (KBr)/cm-1 3335 (OH) and 1704 (C=O); δH (400MHz; 
CDCl3) 3.60 (1H, d, J=6.8Hz, OH), 3.74 (3H, s, OCH3), 5.74 and 6.45 (2H, 2xs, C=CH2), 
6.17 (1H, d, CHOH), 7.39 (1H, t, J=7.8Hz, 4’-H), 7.52 (1H, d, J=7.6Hz, 5’-H) and 7.60 (1H, 
d, J=8Hz, 3’-H); δC (100MHz; CDCl3) 52.2 (OCH3), 69.0 (C-3), 122.9 (C-5’), 127.9 (C=CH2), 
129.4 (C-4’), 131.6 (C-1’), 133.4 (C-3’), 135.6 (C-6’), 137.9 (C=CH2), 151.5 (C-2’) and 
166.33 (C=O); m/z 272 [M+1 (35Cl), 38%], and 155 (100%),  
 
Methyl 3-hydroxy-2-methylene-3-(4,5-methylenedioxy-2-nitrophenyl)propanoate 26j 
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The general procedure was followed, using 3,4-methylenedioxy-2-nitrobenzaldehyde (3.1g, 
15mmol), methyl acrylate (2.1mL, 23mmol), DABCO (86mg, 0.77mmol) and CHCl3 (5mL), 
and the reaction was terminated after 3 weeks. The crude product was purified by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:1)] to afford, as a pale-yellow 
solid, methyl 3-hydroxy-2-methylene-3-(4,5-methylenedioxy-2-nitrophenyl)-propanoate 26j 
(2.4g, 54%), m.p. 128-129°C (lit.76 121-123°C); νmax (KBr)/cm-1 3486 (OH) and 1716 (C=O); 
δH (400MHz; CDCl3) 3.45 (1H, d, J=4.4Hz, OH), 3.74 (3H, s, OCH3), 5.68 and 6.32 (2H, 2xs, 
C=CH2), 6.11 (2H, s, OCH2O), 6.17 (1H, d, J=3.2Hz, CHOH), 7.15 (1H, s, 6’-H) and 7.48 
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(1H, s, 3’-H); δC (100MHz; CDCl3) 52.2 (OCH3), 67.7 (C-3), 103.1 (OCH2O), 105.5 (C-3’), 
107.7 (C-6’), 126.1 (C=CH2), 133.6 (C-1’), 140.9 (C=CH2), 142.2 (C-2’), 147.3 (C-5’), 152.2 
(C-4’) and 166.5 (C=O); m/z 281 (M+, 2%) and 176 (100%). 
 
Methyl 3-(2,4-dinitrophenyl)-3-hydroxy-2-methylenepropanoate 26k 
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The general procedure was followed, using 2,4-dinitrobenzaldehyde (0.55g, 2.8mmol), methyl 
acrylate (0.34mL, 4.2mmol), 3-HQ (16mg, 0.13mmol) and CHCl3 (0.5mL). The reaction 
mixture was stirred for 7 days and the crude product was purified by flash chromatography on 
silica gel [elution with hexane-EtOAc (3:1)] to afford, as a red solid, methyl 3-(2,4-
dinitrophenyl)-3-hydroxy-2-methylenepropanoate 26k (0.8g, 96%), m.p. 84-86°C (lit.53 82-
85°C); νmax (KBr)/cm-1 3449 (OH) and 1724 (C=O); δH (400MHz; CDCl3), 3.59 (1H, br s, 
OH), 3.74 (3H, s, OCH3), 5.74 and 6.39 (2H, 2xs, C=CH2), 6.28 (1H, s, CHOH), 8.02 (1H, d, 
J=8.8Hz, 6’-H), 8.46 (1H, dd, J=2.0 and 8.8Hz, 5’-H) and 8.77 (1H, d, J=2.4Hz, 3’-H); δC 
(100MHz; CDCl3) 52.4 (OCH3), 67.5 (C-3), 120.0 (C-3’), 127.3 (C-5’), 127.4 (C=CH2), 
130.7 (C-6’), 130.8 (C-2), 142.7 (C-1’), 147.2 (C-4’), 148.1 (C-2’) and 166.0 (C=O); m/z 283 
(M+1, 9%) and 149 (100%). 
 
3-Methyleneheptan-2,6-dione 30c-e  
CH3 1
2
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The MVK dimer 30 was isolated as a competition product together with each of the Baylis-
Hillman adducts 26c,d,e as a reddish-brown oil; νmax (KBr)/cm-1 1698 (C=O); δH (400MHz; 
CDCl3) 2.10 and 2.30 (6H, 2xs, 2xCH3), 2.54 (4H, m, 4- and 5-CH2) and 5.80 and 6.00 (2H, 
2xs, C=CH2); δC (100MHz; CDCl3) 25.3 (C-7), 42.4 (C-1), 56.4 and 56.5 (C-4 and C-5), 
126.2 (C=CH2), 140.0 (C-3), 199.0 and 207.6 (2xC=O). 
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3.3 Hydrogenation of Baylis-Hillman products 
 
Attempted preparation of 2,3-dimethylquinoline 35a 
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To a solution of 4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 26a (1.0g, 4.5mmol) in 
ethanol (50mL), 10% Pd-C catalyst (0.16g) was added and the resulting mixture was stirred 
under a hydrogen atmosphere for 1.5 hours. The reaction mixture was filtered to remove 
catalyst and concentrated in vacuo. The crude mixture was re-dissolved in CH2Cl2 and dried 
with anhydrous MgSO4.52 The solvent was evaporated in vacuo and the 1H NMR spectrum of 
the solid showed that the reaction had been unsuccessful.  
 
6-Hydroxy-2,3-dimethylquinoline 35b and 6-hydroxy-2,3-dimethylquinoline-N-oxide 39b 
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To a solution of 4-hydroxy-3-methylene-4-(5-hydroxy-2-nitrophenyl)butan-2-one 26b (1.3g, 
5.7mmol) in ethanol (50mL), 10% Pd-C catalyst (0.24g) was added and the resulting mixture 
was stirred under hydrogen for 3 hours. The reaction mixture was filtered to remove the 
catalyst and the filtrate concentrated in vacuo. The crude mixture was re-dissolved in CH2Cl2 
and dried with anhydrous MgSO4.52 The residue was dissolved in ethyl acetate from which a 
brown precipitate formed and was filtered off. The brown precipitate was shown by NMR 
analysis to comprise a mixture of 6-hydroxy-2,3-dimethylquinoline 35b [δH (400MHz; 
DMSO-d6) 2.34 (3H, s, 3-CH3), 2.51 (3H, s, 2-CH3), 7.01 (1H, d, J=2.4Hz, 5-H), 7.17 (1H, dd, 
J=2.4 and 8.8Hz, 7-H), 7.71 (1H, d, J=9.2Hz, 8-H), 7.78 (2H, s, 4-H) and 9.98 (OH); δC 
(100MHz; DMSO-d6) 19.0 (3-CH3), 22.8 (2-CH3), 107.5 (C-5), 120.4 (C-7), 128.2 (C-9), 
129.9 (C-8), 129.9 (C-3), 133.2 (C-4), 141.0 (C-2), 154.7 (C-6) and 154.9 (C-10); m/z 173 
(M+, 100%)] and 6-hydroxy-2,3-dimethylquinoline-N-oxide 39b (1.10g) [δH (400MHz; 
DMSO-d6) 2.63 (3H, s, 3-CH3), 2.48 (3H, s, 2-CH3), 7.08 (1H, d, J=2.4Hz, 5-H), 7.20 (1H, dd, 
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J=2.4 and 9.6Hz, 7-H), 7.48 (1H, s, 4-H), 8.33 (1H, d, J=9.2Hz, 8-H) and 9.98 (OH); δC 
(100MHz; DMSO-d6) 14.0 (2-CH3), 19.6 (3-CH3), 108.4 (C-5), 120.7 (C-8), 120.7 (C-7), 
122.7 (C-4), 131.3 (C-3), 134.0 (C-10), 142.4 (C-2) and 156.5 (C-9); m/z 189 (M+, 33%)].  
 
3-Acetoxymethyl-2-methyl-6,7-methylenedioxyquinoline 44c 
3
2
4
N
1
10
97
8
6
5 11
O
12
CH313
O
O
O CH3
    
A mixture of 4-hydroxy-3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one 26c 
(0.11g, 0.42mol) in acetic acid (2.6mL), was heated to 110°C. Iron powder (0.14g, 2.5mmol) 
was added and the resulting mixture refluxed for 1.5 hours. The excess acetic acid was 
removed under reduced pressure; the residue was dispersed in EtOAc (15mL), and the 
dispersion stirred for 2 min and filtered to remove the iron powder. The insoluble iron powder 
was washed with EtOAc (2x10mL). The filtrate and washings were combined and 
concentrated in vacuo. Flash chromatography on silica gel (elution with hexane-EtOAc 
[1.5:1]) afforded, as a light-yellow powder, 3-acetoxymethyl-2-methyl-6,7-
methylenedioxyquinoline 44c (20mg, 20%) (Found M+: 259.0848. Calc. for C14H13NO4, M: 
259.0844); δH (600MHz, CDCl3) 2.12 (3H, s, CH3CO), 2.66 (3H, s, 2-CH3), 5.21 (2H, s, 
OCH2), 6.08 (2H, s, OCH2O), 7.01 (1H, s, 5-H), 7.30 (1H, s, 8-H) and 7.87 (1H, s, 4-H); δC 
(100MHz, DMSO-d6) 20.9 (CH3CO), 22.4 (2-CH3), 64.1 (OCH2), 101.6 (OCH2O), 102.6 (C-
5), 105.2 (C-8), 123.4 (C-9), 125.8 (C-3), 135.5 (C-4), 145.8 (C-10), 147.5 (C-7), 150.9 (C-6), 
155.5 (C-2) and 170.8 (C=O); m/z 259 (M+, 0.14%) and 144 (100%). 
 
3.4 Perkin-type condensation of quinolines to styrylquinolines  
 
(E) 2-Styrylquinoline 47 
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To a solution of quinaldine (1.0mL, 7.4mmol), in acetic anhydride (12mL) was added 
benzaldehyde (1.5mL, 15mmol). The reaction mixture was refluxed for 16 hours and then 
concentrated in vacuo. The black crystals, which slowly crystallised out were recrystallised 
from chloroform-hexane to afford, as a yellow powder, (E) 2-styrylquinoline 47 (0.51g, 
30%),m.p. 92-94°C (lit.77 97-100°C); νmax (KBr)/cm-1 1594 (N=C); δH (400MHz; CDCl3) 7.32 
(1H, t, J=7.2Hz, 16-H), 7.39 (3H, m, 12-, 15- and 17-H), 7.49 (1H, t, J=7.2Hz, 6-H), 7.63-
7.71 (5H, m, 4-, 7-, 11-, 14- and 18-H), 7.78 (1H, d, J=8Hz, 5-H) and 8.10 (2H, m, 3- and 8-
H); δC (100MHz; CDCl3) 119.2 (C-4), 126.2 (C-6), 127.3 (C-14 and C-18), 127.3 (C-13), 
127.5 (C-5), 128.6 (C-16), 128.8 (C-15 and C-17), 129.0 (C-12), 129.2 (C-8), 129.7 (C-7), 
134.5 (C-11), 136.4 (C-3), 136.5 (C-10), 148.2 (C-2), and 156.0 (C-9); m/z 231 (M+, 48%) 
and 230 (100%). 
 
Attempted preparation of 5-hydroxy-4-methylene-5-(2-nitrophenyl)-1-phenylpent-1-en-3-
one 48a 
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Method A: A solution of 4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 26a (0.1g, 
0.4mmol), benzaldehyde (0.08mL, 0.8mmol) and acetic anhydride (1.2mL) was refluxed 
under N2 for 16 hours. The crude mixture was added to a mixture of crushed ice and saturated 
aq. NaHCO3 (20mL) and the resulting mixture stirred overnight before extracting with ethyl 
acetate (10mL). The organic layer was dried with anhydrous MgSO4 and concentrated in 
vacuo, but 1H and 13C NMR analysis of the residue indicated that compound 48a was not 
present. 
 
Method B: A solution of 4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 26a (0.1g, 
0.4mmol), benzaldehyde (0.08mL, 0.8mmol) and acetic anhydride (1.2mL) was treated with 
microwave radiation (150W) with maximum pressure of 150KPa for 10 minutes. The 
resulting solution was cooled and stirred with crushed ice and saturated aq. NaHCO3 (20mL) 
overnight. The mixture was extracted ethyl acetate and the organic layer dried with anhydrous 
MgSO4 and concentrated in vacuo, but 1H NMR analysis indicated that the desired product 
48a had not formed.  
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Attempted preparation of 5-hydroxy-4-methylene-5-(4,5-methylenedioxy-2-nitrophenyl)-1-
phenylpent-1-en-3-one 48c 
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A solution of 4-hydroxy-3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one 26c 
(0.10g, 0.38mmol), benzaldehyde (0.08mL, 0.8mmol) and acetic anhydride (1.2mL) was 
refluxed under N2 for 16 hours. The crude mixture was added to crushed ice and saturated aq. 
NaHCO3 (20mL) was added and the resulting mixture was stirred overnight before extracting 
with ethyl acetate (10mL). The organic layer was dried with anhydrous MgSO4 and was 
concentrated in vacuo, but 1H and 13C NMR analysis of the residue indicated that the reaction 
had not been successful. 
 
3.5 Substitution reactions of Baylis-Hillman products  
 
3-Chloromethyl-4-(5-hydroxy-2-nitrophenyl)but-3-en-2-one 52b 
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Acetyl chloride (7mL) was added dropwise to dry ethanol (12mL), cooled in ice, and the 
mixture was stirred for 5 minutes before adding 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-
methylenebutan-2-one 26b (0.96g, 4.1mmol). The resulting mixture was stirred for 10 hours 
and the excess HCl and solvent were evaporated in vacuo to afford, as a yellow-brown solid, 
3-chloromethyl-4-(5-hydroxy-2-nitrophenyl)but-3-en-2-one 52b (0.97g, 94%), m.p. 141-
144°C; νmax KBr/cm-1 3279 (OH) and 1662 (C=O); δH (400MHz; CDCl3) 2.44 (3H, s, CH3), 
4.18 (2H, s, 11-CH2), 6.86 (1H, d, J=2Hz, 10-H), 6.98 (1H, dd, J=2.4 and 9.2Hz, 8-H), 8.12 
(1H, s, 4-H), 8.17 (1H, d, J=9.2Hz, 7-H) and 8.18 (1H, s, OH); δC (100MHz; CDCl3); δC 
(100MHz; CDCl3) 26.3 (C-1), 37.8 (C-11), 112.4 (C-10), 116.7 (C-8), 128.5 (C-7), 133.6 (C-
6), 136.0 (C-3), 138.7 (C-5), 143.3 (C-4), 163.2 (C-9) and 197.8 (C=O). 
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3-Chloromethyl-4-(4,5-methylenedioxy-2-nitrophenyl)but-3-en-2-one 52c 
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Acetyl chloride (18mL) was added dropwise to dry ethanol (30mL), cooled in ice, and the 
mixture was stirred for 5 minutes before adding 4-hydroxy-3-methylene-4-(4,5-
methylenedioxy-2-nitrophenyl)butan-2-one 52c (3.0g, 11mmol). The resulting mixture was 
stirred overnight and the excess HCl and ethanol were evaporated in vacuo to afford, as a 
black wax, 3-chloromethyl-4-(4,5-methylenedioxy-2-nitrophenyl)but-3-en-2-one 58c (3.20g, 
100%); νmax KBr/cm-1 1664 (C=O); δH (400MHz; CDCl3) 2.50 (3H, s, COCH3), 4.21 (2H, s, 
11-CH2), 6.21 (2H, s, -OCH2O-), 7.11 (1H, s, 10-H), 7.72 (1H, s, 7-H), and 7.92 (1H, s, 4-H); 
δC (100MHz; CDCl3) 26.0 (C-1), 37.1 (C-11), 103.6 (-OCH2O-), 106.0 (C-7), 109.03 (C-10), 
126.9 (C-5), 137.2 (C-3), 140.9 (C-4), 141.6 (C-6), 148.8 (C-9), 152.5 (C-8), and 196.8 
(C=O). 
 
3-Chloromethyl-4-(5-chloro-2-nitrophenyl)but-3-en-2-one 52f 
3
11
4
NO2
5
68
7
9
10
Cl
2
CH31
O
Cl
 
Acetyl chloride (20mL) was added dropwise to dry ethanol (40mL), cooled in ice, and the 
mixture was stirred for 5 minutes before adding 4-(5-chloro-2-nitrophenyl)-4-hydroxy-3-
methylenebutan-2-one 26f. The resulting mixture was stirred for 10 hours and the excess HCl 
and solvent were evaporated in vacuo to afford, as a black oil, 3-chloromethyl-4-(5-chloro-2-
nitrophenyl)but-3-en-2-one 52f (3.8g, 94%); νmax KBr/cm-1 1677 (C=O); δH (400MHz; CDCl3) 
2.51 (3H, s, CH3), 4.17 (2H, s, 11-CH2), 7.56 (1H, dd, J=1.0 and 8.8Hz, 8-H), 7.67 (1H, d, 
J=1.2Hz, 10-H), 7.91 (1H, s, 4-H) and 8.18 (1H, d, J=8.8Hz, 7-H); δC (100MHz; CDCl3) 26.0 
(CH3), 36.7 (C-11), 126.7 (C-7), 130.2 (C-8), 130.4 (C-10), 131.9 (C-5), 138.3 (C-3), 138.8 
(C-4), 140.8 (C-6), 145.2 (C-9) and 196.3 (C=O).  
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3.6 Conjugate addition reactions of Baylis-Hillman adducts  
 
General Method: A solution of the Baylis-Hillman product (1eq.), and the specified amine 
(1.5eq.) in dry THF or methanol was stirred in a stoppered flask at room temperature for 
periods which varied according to the reactants involved. The solution was then concentrated 
in vacuo to afford the aminated product. 1H NMR and 13C NMR data are cited for the major 
diastereoisomeric product in each case. 
 
Methyl 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58g 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)-
propanoate 26g (1.40g, 6.32mmol), piperidine (0.54mL, 5.5mmol) and dry THF (5mL). After 
3days, the mixture was concentrated in vacuo and the crude product purified by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:1)] to afford a yellow solid, 
comprising a 2:1 diastereomeric mixture of methyl 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-
1-yl)methyl]propanoate 58g (1.5g, 74%), m.p. 59-61 °C (lit.76 76-78°C); νmax (KBr)/cm-1 3473 
(OH) and 1714 (C=O); δH (400MHz; CDCl3) 1.44 (2H, m, 13-CH2), 1.54-1.64 (4H, m, 12- 
and 14-CH2), 2.45 (4H, m, 11- and 15-CH2), 2.70 and 3.01 (2H, 2xm, 10-CH2), 3.16 (1H, m, 
2-CH), 3.44 (3H, s, CH3), 5.52 (1H, d, J=8.8Hz, 3-H), 7.38 (1H, m, 7-H), 7.55 (1H, t, 
J=7.6Hz, 8-H) and 7.60-7.75 (2H, m, 9- and 6-H); δC (100MHz; CDCl3) 23.8 (C-13), 25.8 (C-
12 and C-14), 48.3 (C-2), 51.8 (CH3), 55.0 (C-11 and C-15), 60.7 (C-10), 73.1 (C-3), 124.7 
(C-6), 128.4 (C-7), 129.8 (C-9), 132.3 (C-8), 136.5 (C-4), 149.0 (C-5) and 171.4 (C=O); m/z 
323 (MH+, 2.5%) and 98 (100%).  
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Methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58h 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(3-methoxy-2- 
nitrophenyl)propanoate 26h (1.3g, 4.9mmol), piperidine (0.43mL, 4.2mmol) and dry THF 
(5mL). After 3 days, the mixture was concentrated in vacuo and the crude product purified by 
flash chromatography on silica gel (elution with hexane-EtOAc [1:1]) to afford, as a brick-red 
wax, a 5:3 diastereomeric mixture of methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-
[(piperdin-1-yl)methyl]propanoate 58h (1.1g, 76%, lit.76 cited as brown oil) (Found M+1: 
353.1724. Calc. for C17H25N2O6: MH+, 353.1713); νmax (KBr)/cm-1 3362 (OH) and 1743 
(C=O); δH (400MHz; CDCl3) 1.38-1.62 (6H, m, 12-, 13- and 14-CH2), 2.40 (4H, m, 11- and 
15-CH2), 2.68 and 2.98 (2H, m, 10-CH2), 3.28 (1H, m, 2-H), 3.46 (3H, s, CO2CH3), 3.85 (3H, 
s, Ar-OCH3), 5.05 (1H, m, 3-H), 6.91-6.95 (2H, m, 7- and 9-H) and 7.32 (1H, t, J=8.4Hz, 8-
H); δC (100MHz; CDCl3) 23.8 (C-13), 25.7 (C-12 and C-14), 47.5 (C-2), 51.8 (CO2CH3), 54.8 
(C-11 and C-15), 56.4 (Ar-OCH3), 61.0 (C-10), 75.2 (C-3), 111.9 (C-7), 120.0 (C-9), 130.4 
(C-8), 134.9 (C-4), 140.3 (C-4), 150.8 (C-6) and 171.4 (C=O). 
 
Methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2-[(piperidin-1-yl)methyl]propanoate 58i 
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The general method was followed, using methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2- 
methylenepropanoate 26i (0.50g, 1.9mmol), piperidine (0.27mL, 2.8mmol) and dry THF 
(5mL). After 3 days, the mixture was concentrated in vacuo and the crude product purified by 
flash chromatography on silica gel [elution with hexane-EtOAc (3:2)] to afford, as a black oil,  
a 10:7 diastereomeric mixture of methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2-[(piperidin-
1-yl)methyl]propanoate 58i (0.4g, 61%) [Found M+1 (35Cl): 357.1209. Calc. for 
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C16H22N2O5Cl: MH+, 357.1217); νmax KBr/cm-1 3331 (OH) and 1741 (C=O); δH (400MHz; 
CDCl3) 1.52 (6H, m, 12-, 13- and 14-CH2), 2.49 and 2.59 (2H, 2xm, 10-CH2), 3.12 (4H, m, 
11- and 12-CH2), 3.54 (1H, m, 2-H), 3.70 (3H, s, OCH3), 5.59 (1H, d, J=8.4Hz, 3-H), 7.31 
(1H, t, J=8Hz, 7-H), 7.44 (1H, d, J=8Hz, 6-H) and 7.52 (1H, d, J=8Hz, 8-H); δC (100MHz; 
CDCl3) 25.7 (C-11 and C-15), 47.9 (C-12 and C-14), 48.5 (C-2), 52.0 (OCH3), 54.5 (C-13), 
57.6 (C-10), 70.3 (C-3), 122.8 (C-6), 128.7 (C-7), 132.9 (C-8), 133.2 (C-4), 134.9 (C-9), 
151.3 (C-5) and 173.7 (C=O). 
 
Methyl 3-hydroxy-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propan-
oate 58j 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(4,5-
methylenedioxy-2-nitrophenyl)propanoate 26j (0.51g, 1.8mmol), piperidine (0.27mL, 
2.7mmol) and dry THF (5mL). After 2 days, the solvent was removed in vacuo and the crude 
product was purified by flash chromatography on silica gel [elution with hexane-EtOAc (3:2)] 
to afford, as a brown wax, a 4:1 diastereomeric mixture of methyl 3-hydroxy-3-(4,5-
methylenedioxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]-propanoate 58j (0.63g, 95%), (lit.76 
m.p. 102-105°C); νmax (KBr)/cm-1 3338 (OH) and 1713 (C=O); δH (400MHz; CDCl3) 1.44 
(2H, m, 13-CH2), 1.59 (4H, m, 12- and 14-CH2), 2.50 (4H, m, 11- and 15-CH2), 2.72 and 3.01 
(2H,m, 10-CH2), 2.94 (1H, m, 2-H). 3.47 (3H, s, CH3), 5.62 (1H, d, J=8Hz, 3-H), 6.06 (2H, s, 
OCH2O), 7.17 (1H, s, 9-H) and 7.27 (1H, s, 6-H); δC (100MHz; CDCl3) 23.8 (C-11 and C-15), 
25.7 (C-12 and C-14), 48.6 (C-2), 51.9 (CH3), 54.6 (C-13), 60.2 (C-10), 72.1 (C-3), 103.8 
(OCH2O), 104.7 (C-6), 107.9 (C-9), 134.4 (C-4), 142.5 (C-5), 147.0 (C-8), 152.5 (C-7) and 
171.2 (C=O); m/z 367(M+1, 2.8%) and 98 (100%). 
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Methyl 3-(2,4-dinitrophenyl)-3-hydroxy-2-[(piperidin-1-yl)methyl]propanoate 58k 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(2,4-
dinitrophenyl)propanoate 26k (0.90g, 3.2mmol), piperidine (0.47mL, 4.8mmol) and dry THF 
(5mL). After 3 days, the solvent was removed in vacuo and the crude product was purified by 
flash chromatography on silica gel [elution with hexane-EtOAc (3:1)] to afford, as a reddish-
brown oil, a 5:2 diastereomeric mixture of methyl 3-(2,4-dinitrophenyl)-3-hydroxy-2-
[(piperidin-1-yl)methyl]propanoate 58k (0.67g, 57%), (lit.76 cited as brown oil) (Found M+1: 
368.1465. Calc. for C16H22N3O7: MH+, 368.1458); νmax (KBr)/cm-1 3317 (OH) and 1723 
(C=O); δH (400MHz; CDCl3) 1.47 (2H, m, 13-CH2), 1.62 (4H, m, 12- and 14-CH2), 2.43 and 
2.70 (2H, 2xm, 11- and 15-CH2), 2.77 and 3.06 (2H, 2xm, 10-CH2), 3.14 (1H, m, 2-H), 3.49 
(3H, s, CH3), 5.61 (1H, d, J=8.8Hz, 3-H), 7.91 (1H, d, J=8.8Hz, 9-H), 8.37 (1H, dd, J=8.8 and 
1.6Hz, 8-H) and 8.57 (1H, d, J=1.6Hz, 6-H); δC (100MHz; CDCl3) 23.7 (C-13), 25.7 (C-12 
and C-14), 47.8 (C-2), 52.1 (CH3), 54.8 (C-11 and C-15), 60.7 (C-10), 73.0 (C-3), 119.6 (C-6), 
126.4 (C-8), 131.2 (C-9), 140.3 (C-7), 143.6 (C-4), 148.8 (C-5) and 170.9 (C=O). 
 
Methyl 2-[(2-carbomethoxypyrrolidin-1-yl)methyl]-3-hydroxy-3-(2-nitrophenyl)propanoate 
59g 
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Method A: To a solution of methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 26g 
(0.54g, 2.3mmol) and L-proline methyl ester hydrochloride (0.35g, 2.2mmol) in THF (5mL) 
was added proton sponge (0.67g, 3.1mmol), and the resulting mixture stirred in a stoppered 
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flask at room temperature for 14 days. The solvent was removed in vacuo and the residue was 
washed with ethyl acetate. The insoluble proton sponge was filtered off and the ethyl acetate 
was evaporated from the filtrate, but 1H NMR analysis of the residue showed that the desired 
product 59g not formed. 
 
Method B: A solution of methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 26g 
(0.54g, 2.3mmol), L-proline methyl ester hydrochloride (0.71g, 4.3mmol) and triethylamine 
(0.28mL, 2.0mmol) in methanol (5mL) was stirred for 7 days, and the reaction mixture was 
then concentrated in vacuo. Addition of ethyl acetate gave a reddish-yellow solid, which was 
filtered off; the filtrate was concentrated in vacuo and chromatographed by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:1)] to afford three fractions 
comprising diastereomers of methyl 2-[(2-carbomethoxypyrrolidin-1-yl)methyl]-3-hydroxy-3-
(2-nitrophenyl)propanoate 59g 
 
Fraction 1: Diastereomer 59g1 as a yellow oil (89mg, 11%), (Found M+1: 367.1505. Calc. 
for C17H23N2O7: MH+, 367.1505); νmax KBr/cm-1 3424 (OH) and 1732 (C=O); δH (400MHz; 
CDCl3) 1.90 (3H, m, 12-CH2 and 13-CHA), 2.21 (1H, m, 13-CHB), 2.35 (1H, q, J=8.2Hz, 11-
CHA), 2.56 (1H, dd, J=3.2Hz, 10-CHA), 3.25 (3H, s, 1-OCH3), 3.33 (3H, m, 2-CH, 10-CHB 
and 14-CH), 3.50 (1H, m, 11-CHA), 3.75 (3H, s, 15-OCH3), 5.98 (1H, d, J=2.8Hz, 3-H), 7.39 
(1H, t, J=8.6Hz, 7-H), 7.61 (1H, t, J=8.2Hz, 8-H), 7.87 (1H, d, J=8Hz, 9-H) and 8.01 (1H, d, 
J=8Hz, 6-H); δC (100MHz; CDCl3) 23.5 (C-12), 29.3 (C-13), 49.2 (C-2), 51.0 (1-OCH3), 52.3 
(15-OCH3) 52.4 (C-10), 53.2 (C-11), 65.7 (C-14), 66.7 (C-3), 124.4 (C-6), 127.7 (C-7), 128.7 
(C-9), 133.2 (C-8), 138.2 (C-5), 147.0 (C-4), 171.9  and 176.1 (2xC=O). 
 
Fraction 2: as a yellow oil (0.31mg, 37%), comprising a mixture of two diastereoisomers 
59g2,3 (NMR data cited for major stereoisomer) (Found M+1: 367.1512. Calc for C17H23N2O7: 
MH+, 367.1505); νmax KBr/cm-1 3410 (OH) and 1739 (C=O); δH (400MHz; CDCl3) 1.81 (2H, 
m, 12-CH2), 2.06 (2H, m, 11-CH2), 2.57 (1H, q, J=7.6Hz, 13-CHA), 3.02-3.35 (5H, m, 14-H, 
2-H, 10-CH2, and 13-CHB ), 3.45 (3H, s, 1-OCH3), 3.64 (3H, s, 15-OCH3), 5.62 (1H, d, 
J=7.2Hz, 3-H), 7.30 (1H, m, 8-H), 7.50 (1H, m, 7-H) and 7.71 (2H, d, J=8Hz, 6-H and 9-H); 
δC (100MHz; CDCl3) 23.3 (C-12), 29.0 (C-11), 50.0 (C-2), 51.7 (2xOCH3), 52.9 (C-13), 53.9 
(C-10), 65.6 (C-14), 70.0 (C-3), 123.8 (C-6), 128.1 (C-8), 129.1 (C-9), 132.5 (C-7), 136.8 (C-
5), 148.3 (C-4), 172.3 (C-1) and 174.0 (C-15). 
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Fraction 3: Diastereomer 59g4 as pale yellow oil (69mg, 6%), (Found M+1: 367.1509. Calc 
for C17H23N2O7: MH+, 367.1505); νmax KBr/cm-1 3450 (OH) and 1730 (C=O);δH (400MHz; 
CDCl3) 1.86-2.01 (4H, m, 12- and 13-CH2), 2.54 (1H, q, J=7.6-11.6Hz, 11-HA), 2.85 (1H, dd, 
J=4.8Hz, 10-HA), 3.15 (2H, m, 11-HB and 2-H), 3.30 (1H, m, 10-HB), 3.39 (1H, m, 14-H), 
3.50 (3H, s, 1-OCH3), 3.67 (15-OCH3), 5.45 (1H, d, J=3.2Hz, 3-H), 7.40 (1H, t, J=7.6Hz, 8-
H), 7.61 (1H, t, J=8Hz, 7-H), 7.10 (1H, d, J=7.6Hz, 9-H) and 7.95 (1H, d, J=8Hz, 6-H); δC 
(100MHz; CDCl3) 23.4 (C-12), 29.0 (C-13), 50.1 (C-2), 51.6 (2xOCH3), 53.1 (C-11), 54.5 (C-
10), 54.3 (C-14), 69.2 (C-3), 124.6 (C-6), 138.3 (C-8), 128.4 (C-9), 133.3 (C-7), 138.2 (C-5), 
147.3 (C-4), 173.9 (C1) and 174.0 (C15).  
 
N,N’-Bis[2-carbomethoxy-3-hydroxy-3-(2-nitrophenyl)propyl]-1,4-piperazine 62g  
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)- 
propanoate 26g (1.30g, 5.48mmol), piperazine (0.41g, 4.78mmol) and dry THF (5mL). After 
24 hours the solvent was removed in vacuo and the crude product was purified by flash 
chromatography on silica gel (elution with hexane-EtOAc [1:1]) to afford, as a yellowish-
green solid, a 2:3 diastereomeric mixture of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(2-
nitrophenyl)propyl]-1,4-piperazine 62g  (0.74g, 24%), m.p. 78-82°C (Found M+1: 561.2214. 
Calc. for C26H33N4O10, MH+: 561.2197); νmax KBr/cm-1 3353 (OH) and 1732 (C=O);  δH 
(400MHz; CDCl3)# 2.77 and 3.03 (4H, 2xm, 1- and 1’-CH2), 3.26 (2H, m, 2- and 2’-H), 3.50 
(6H, s, 2xOCH3), 3.78 (8H, m, 11-, 11’-, 12- and 12’-CH2), 5.54 (2H, d, J=5.2Hz, 3- and 3’-
H), 7.40 (2H, t, J=4.8Hz, 8- and 8’-H), 7.56 (2H, t, J=5.0Hz, 7- and 7’-H), 7.62 (2H, d, 
J=4.4Hz, 9- and 9’-H) and 7.75 (2H, d, J=5.6Hz, 6- and 6’-H); δC (100MHz; CDCl3) 47.9 (C-
2 and C-2’), 52.0 (2xOCH3), 52.1 (C-11, C-11’, C-12 and C-12’), 59.2 (C-1 and C-1’), 73.3 
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(C-3 and C-3’), 124.3 (C-6 and C-6’), 128.6 (C-8 and C-8’), 129.3 (C-9 and C-9’), 132.4 (C-7 
and C-7’), 136.1 (C-5 and C-5’), 149.0 (C-4 and C-4’) and 171.7 (2xC=O). 
# NMR data cited for the major product. 
 
N,N’-Bis[2-carbomethoxy-3-hydroxy-3-(3-methoxy-2-nitrophenyl)propyl]-1,4-piperazine 
62h 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(3-methoxy-2- 
nitrophenyl)propanoate 26h (1.31g, 4.86mmol), piperazine (0.37g, 4.3mmol) and dry THF 
(5mL). After 6 hours the mixture was concentrated in vacuo and the crude product purified by 
flash chromatography on silica gel (elution with hexane-EtOAc [3:1]) to afford, as a yellow 
oil, a 5:3 diastereomeric mixture of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(3-methoxy-2-
nitrophenyl)propyl]-1,4-piperazine 62h (0.12g, 4.3%) (Found M+1: 621.2392. Calc. for 
C28H37N4O12, MH+: 621.2408); νmax KBr/cm-1 3358 (OH) and 1730 (C=O); δH (400MHz; 
CDCl3)# 2.14-2.74 (10H, m, 1- and 1’-CHA, 11-, 11’-, 12- and 12’-CH2), 3.04 (2H, m, 1- and 
1’-CHB), 3.28 (2H, m, 2- and 2’-CH), 3.61(6H, 2xm, 1- and 1’-OCH3), 3.85 (6H, m, 2xAr-
OCH3), 5.07 (2H, 2xm, 3- and 3’-CH), 6.87 (2H, 2xm, 9- and 9’-H), 6.94 (2H, m, 7- and 7’-H) 
and 7.31 (2H, 2xm, 8- and 8’-H); δC (100MHz; CDCl3) 47.3 (C-2 and C-2’), 51.9 (1-and 1’-
OCH3), 56.6 (C-11, C-11’, C-12 and C-12’), 56.4 (6- and 6’-OCH3), 59.7 and 60.0 (C-10 and 
C-10’), 75.3 (C-3 and C-3’), 112.0 (C-7 and C-7’), 119.9 (C-9 and C-9’), 130.4 (C-8 and C-
8’), 134.5 (C-4 and C-4’), 140.2 (C-5 and C-5’), 151.0 (C-6 and C-6’) and 171.2 (2xC=O).  
# NMR data cited for the major product.
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N,N’-Bis [2-carbomethoxy-3-hydroxy-3-(6-chloro-2-nitrophenyl)propyl]-1,4-piperazine 62i 
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The general method was followed, using methyl 3-(6-chloro-2-nitrophenyl)-3-hydroxy-2- 
methylenepropanoate 26i (0.50g, 1.9mmol), piperazine (0.24g, 2.8mmol) and dry THF (5mL). 
After 3 days the solvent was removed in vacuo and the crude product was purified by flash 
chromatography on silica gel [elution with hexane-EtOAc (3:2)] to afford, as a yellow solid,  
a 2:1 diastereomeric mixture of homodimers of N,N’-bis[2-carbomethoxy-3-hydroxy-3-(6-
chloro-2-nitrophenyl)propyl]-1,4-piperazine 62i (30mg, 3%), (Found M+1: 629.1357. Calc. 
for C26H31N4O10Cl2, MH+: 629.1417); νmax KBr/cm-1 3375 (OH) and 1728 (C=O); δH 
(400MHz; CDCl3)# 2.15 and 2.40 (8H, 2xm, 11-, 11’-, 12- and 12’-CH2), 2.54 (4H, m, 1- and 
1’-CH2), 3.50 (6H, m, 2xOCH3), 3.59 (2H, m, 2- and 2’-H), 5.58 (2H, m, 3- and 3’-H), 7.29-
7.57 (6H, m, ArH); δC (100MHz; CDCl3) 44.3 (C-2 and C-2’), 48.8 (2xOCH3) 52.2 (C-11, C-
11’, C-12 and C-12’), 56.6 (C-1 and C-1’), 73.7 (C-3 and C-3’), 123.0 (2xArC), 128.9 
(2xArC), 133.1 (C-8 and C-8’), 134.9 (C-4 and C-4’), 151.5 (C-9 and C-9’), 170.8 (C-5 and 
C-5’) and 173.4 (2x C=O). 
# NMR data cited for the major product. 
 
N,N’-Bis[2-carbomethoxy-3-hydroxy-3-(4,5-methylenedioxy-2-nitrophenyl)propyl]-1,4-
piperazine 62j 
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The general method was followed, using methyl 3-hydroxy-2-methylene-3-(4,5-
methylenedioxy-2-nitrophenyl)propanoate 26j (0.51g, 1.83mmol), piperazine (0.23g, 
2.6mmol) and dry THF (5mL). After 2 days the solvent was removed in vacuo and the crude 
product was purified using preparative thin layer chromatography on silica gel [elution with 
hexane-EtOAc (3:1)] to afford, as a yellow wax, a 4:1 diastereomeric mixture of N,N’-bi-[2-
carbomethoxy-3-hydroxy-3-(4,5-methylenedioxy-2-nitrophenyl)propyl]-1,4-piperazine 62j 
(40mg, 3%), (Found M+1: 649.1995. Calc. for C28H33N4O14, MH+: 649.1988); νmax KBr/cm-1 
3349 (OH) and 1730 (C=O); δH (400MHz; CDCl3)# 1.23 (8H, m, 11-, 11’-, 12- and 12’-CH2), 
2.77 and 2.99 (4H, 2xm, 1- and 1’-CH2), 2.99 (2H, m, 2- and 2’-H),  3.54 (6H, m, 2xOCH3), 
5.62 (2H, m, 3- and 3’-H), 6.09 (4H, m, 2xOCH2O), 7.15 (2H, s, 9- and 9’-H) and 7.33 (2H, s, 
6- and 6’-H); δC (100MHz; CDCl3) 30.1 (C-11, C-11’, C-12 and C-12’), 48.8 (C-2 and C-2’), 
52.5 (2xOCH3), 59.1 (C-1 and C-1’), 72.3 (C-3 and C-3’), 103.3 (2xOCH2O), 105.5 (C-6 and 
C-6’), 108.3 (C-9 and C-9’), 134.3 (C-5 and C-5’), 142.9 (C-4 and C-4’), 147.6 (C-8 and C-
8’), 152.1 (C-7 and C-7’) and 172.1 (2xC=O). 
# NMR data cited for the major product. 
 
4-(5-Hydroxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 65b 
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The general method was followed, using 3-chloromethyl-4-(5-hydroxy-2-nitrophenyl)but-3-
en-2-one 52b (0.5g, 2mmol), piperidine (0.25mL, 2.9mmol) and dry THF (5mL). The 
reaction was terminated after 6 days, and work-up and purification of the crude product by 
flash chromatography [elution with EtOAc] afforded, as a reddish-brown wax, 4-(5-hydroxy-
2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 65b (0.52g, 86%)  (Found M+1: 
305.1508. Calc. for C16H21N2O4, MH+: 305.1501); νmax KBr/cm-1 3560 (OH) and 1732 (C=O); 
δH (400MHz; CDCl3) 1.27 (6H, m, 13-, 14- and 15-CH2), 2.08 (4H, m, 12- and 16-CH2), 2.41 
(3H, s, CH3), 3.06 (2H, s, 11-CH2), 2.84 (1H, br s, OH), 6.76 (1H, d, J=2.4Hz, 10-H), 6.88 
(1H, dd, J=8.8 and 2.4Hz, 8-H), 7.83 (1H, s, 4-H) and 8.10 (1H, d, J=9.2Hz, 7-H); δC 
(100MHz; CDCl3) 23.6 (C-14), 25.4 (C-13 and C-15), 26.6 (C-1), 53.1 (C-11), 53.5 (C-12 
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and C-16), 115.6 (C-8), 116.9 (C-10), 127.6 (C-7), 135.0 (C-6), 137.5 (C-5), 138.1 (C-3), 
139.3 (C=CH), 163.5 (C-9) and 199.6 (C=O). 
 
4-(4,5-Methylenedioxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 65c 
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The general method was followed, using 3-chloromethyl-4-(4,5-methylenedioxy-2-
nitrophenyl)but-3-en-2-one 52c (0.81g, 2.8mmol), piperidine (0.42mL, 4.2mmol) and dry 
THF (5mL). After 3 days, the mixture was concentrated in vacuo and the crude product 
purified by flash chromatography on silica gel (elution with hexane-EtOAc [3:2]) to afford, as 
a reddish-brown wax, 4-(4,5-methylenedioxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-
en-2-one 65c (0.75g, 79%) (Found M+1: 333.1465. Calc. for C17H21N2O5, MH+: 333.1450); 
νmax KBr/cm-1 1669 (C=O); δH (400MHz; CDCl3) 1.30 (2H, m, 14-CH2) 1.38 (4H, m, 13- and 
15-CH2), 2.18 (4H, m, 12- and 16-CH2), 2.46 (3H, s, CH3), 3.09 (2H, s, 11-CH2), 6.14 (2H, s, 
OCH2O), 7.31 (1H, s, 10-H), 7.62 (1H, s, 7-H) and 7.78 (1H, s, 4-H); δC (100MHz; CDCl3) 
24.1 (C-14), 26.0 (C-13 and C-15), 26.6 (C-1), 53.1 (C-11), 53.9 (C-12 and C-16), 103.2 
(OCH2O), 105.3 (C-7), 110.5 (C-10), 128.7 (C-6), 139.1 (C-4), 139.2 (C-3), 141.9 (C-5), 
147.8 (C-9), 151.7 (C-8) and 200.0 (C=O). 
 
4-(5-Chloro-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 65f 
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The general method was followed, using 3-chloromethyl-4-(5-chloro-2-nitrophenyl)but-3-en-
2-one 52f (0.8g, 3mmol), piperidine (0.43mL, 4.4mmol), and dry THF (5mL). The reaction 
was terminated after 6 days; work-up and purification of the crude product by flash 
chromatography [elution with hexane-EtOAc (3:2)] afforded, as a reddish-brown wax, 4-(5-
chloro-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 65f (0.85g, 90%) (Found 
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M+1: 323.1161. Calc. for C16H20N2O3Cl, MH+: 323.1162); νmax KBr/cm-1 1673 (C=O); δH 
(400MHz; CDCl3) 1.30-1.40 (6H, m, 13-, 14- and 15-CH2), 2.16 (4H, m, 12- and 16-CH2), 
2.48 (3H, s, CH3), 3.07 (2H, s, 11-CH2), 7.44 (1H, dd, J=2.4 and 8.4Hz, 8-H), 8.0 (1H, s, 4-H), 
7.94 (1H, d, J=2.4Hz, 10-H) and 8.08 (1H, d, J=8.8Hz, 7-H); δC (100MHz; CDCl3) 24.0 (C-
14), 26.0 (C-12 and C-15), 26.4 (C-1), 53.1 (C-11), 53.9 (C-12 and C-16), 125.9 (C-7), 128.9 
(C-8), 131.8 (C-10), 133.7 (C-5), 137.4 (C-4), 139.6 (C-9), 140.8 (C-3), 145.8 (C-6) and 
199.4 (C=O). 
 
3-[(2-Carbomethoxypyrrolidin-1-yl)methyl]-4-(4,5-methylenedioxy-2-nitrophenyl)but-3-en-
2-one 66c 
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The general method was followed, using 3-chloromethyl-4-(4,5-methylenedioxy-2-
nitrophenyl)but-3-en-2-one 52c (0.80g, 2.8mmol), L-proline methyl ester hydrochloride 
(0.93g, 5.6mmol), triethylamine (0.79mL, 5.6mmol) and methanol (5mL). After stirring for 7 
days, work-up and  flash chromatography of the crude product on silica gel [elution with 
hexane-EtOAc (1:1)] afforded, as a brown oil, 3-[(2-carbomethoxypyrrolidin-1-yl)methyl]-4-
(4,5-methylenedioxy-2-nitrophenyl)but-3-en-2-one 66c (0.61g, 57%) (Found M+1: 377.1342. 
Calc. for C18H21N2O7, MH+: 377.1349); νmax KBr/cm-1 1734 (C=O); δH (400MHz; CDCl3) 
1.77 (3H, m, 13-CH2 and 14-CHA), 1.99 (1H, m, 14-CHB), 2.29  and 2.87 (2H, 2xm, 12-CH2), 
2.47 (2H, s, 1-CH3), 3.15 (1H, m, 15-CH), 3.34 and 3.52 (2H, 2xd, J=12.4Hz, 11-CH2), 3.61 
(3H, s, 17-CH3), 6.17 (2H, s, OCH2O), 7.33 (1H, s, 10-H), 7.64 (1H, s, 7-H) and 7.80 (1H, s, 
4-H); δC (100MHz; CDCl3) 23.2 (C-13), 26.4 (C-1), 29.6 (C-14), 48.0 (C-11), 51.5 (C-17), 
53.0 (C-12), 64.7 (C-15), 103.23 (OCH2O), 105.5 (C-7), 110.9 (C-10), 128.1 (C-6), 138.7 
(C=CH), 139.2 (C=CH), 141.9 (C-5), 148.1 (C-9), 151.9 (C-8), 174.7 (C-16) and 199.8 (C-2). 
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Ethyl 5-acetyl-2-hydroxymethyl-6-(4,5-methylenedioxy-2-nitrophenyl)-3-aza-5-hexenoate 
67c 
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The general method was followed, using 3-chloromethyl-4-(4,5-methylenedioxy-2-
nitrophenyl)but-3-en-2-one 52c (0.6g, 2.1mmol), L-serine ethyl ester hydrochloride (0.72g, 
4.2mmol) and triethylamine (0.60mL, 4.2mmol) in methanol (5mL). After 4 days, work-up 
and purification of the crude product by flash chromatography [elution with hexane-EtOAc 
(1:1)] afforded, as a reddish-brown wax, ethyl 5-acetyl-6-(4,5-methylenedioxy-2-nitrophenyl)-
2-hydroxymethyl-3-aza-5-hexenoate 67c (0.4g, 52%) (Found M+1: 381.1331. Calc. for 
C17H21N2O8, MH+: 381.1298); δH (400MHz; CDCl3) 1.23 (3H, m, 17-CH3), 2.46 (3H, s, 14-
CH3), 2.74 (2H, m, 15-OH and NH), 3.21 (1H, m, 2-H), 3.34 and 3.47 (2H, 2xm, 4-CH2), 3.55 
and 3.68 (2H, 2xm, 15-CH2), 4.08 (2H, m, 16-CH2), 6.16 (1H, s, OCH2O), 7.00 (1H, s, 12-H), 
7.67 (1H, s, 9-H) and 7.83 (1H, s, 6-H); δC (100MHz; CDCl3) 14.1 (C-17), 25.0 (C-14), 43.5 
(C-4), 62.2 (C-15), 62.5 (C-2), 63.2 (C-16), 103.5 (OCH2O), 105.7 (C-9), 109.7 (C-12), 127.6 
(C-10), 138.8 (C-11), 140.0 (C-6), 141.6 (C-8), 148.5 (C-7), 152.2 (C-5), 172.4 and 200.0 
(2xC=O). 
 
Ethyl 5-acetyl-6-(5-chloro-2-nitrophenyl)-2-hydroxymethyl-3-aza-5-hexenoate 67f 
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The general method was followed, using 3-chloromethyl-4-(5-chloro-2-nitrophenyl)but-3-en-
2-one 52f  (0.41g, 1.5mmol), L-serine ethyl ester hydrochloride (0.50g, 3.0mmol), and 
triethylamine (0.41mL, 3.0mmol) in methanol (5mL). After 7 days, work-up and purification 
of the crude product by flash chromatography [elution with EtOAc] afforded, as a reddish-
brown wax, ethyl 5-acetyl-6-(5-chloro-2-nitrophenyl)-2-hydroxymethyl-3-aza-5-hexenoate 
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67f (0.21g, 36%), (Found M+1: 371.1023. Calc. for C16H20N2O6Cl, MH+: 371.1010); νmax 
KBr/cm-1 3349 (OH) and 1728 (C=O); δH (400MHz; CDCl3) 1.21 (3H, m, 17-CH3), 2.47 (3H, 
s, 14-CH3), 2.77 (2H, br s, 15-OH and NH), 3.19 (1H, m, 2-H), 3.29 and 3.44 (2H, 2xm, 4-
CH2), 3.56 and 3.66 (2H, 2xm, 15-CH2), 4.13 (2H, m, 16-CH2), 7.50 (1H, d, J=8.8Hz, 10-H), 
7.61 (1H, s, 12-H), 7.81 (1H, s, 6-H) and 8.13 (1H, d, J=8.8Hz, 9-H); δC (100MHz; CDCl3) 
14.1 (C-17), 26.0 (C-14), 43.6 (C-4), 61.2 (C-16), 62.4 (C-15), 62.6 (C-2), 126.5 (C-9), 129.7 
(C-10), 131.1 (C-12), 132.7 (C-8), 137.7 (C-6), 140.2 and 140.3 (C-5 and C-7), 145.4 (C-11), 
172.3 and 199.5 (2xC=O). 
 
2-Acetyl-1-(5-hydroxy-2-nitrophenyl)-8-phenyl-4-aza-7-thia-1-octene 68b 
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The general method was followed, using 3-chloromethyl-4-(5-hydroxy-2-nitrophenyl)but-3-
en-2-one 58b (0.93g, 3.3mmol), S-benzylcysteamine hydrochloride (1.3g, 6.6mmol), 
triethylamine (0.92mL, 6.6mmol) and methanol (5mL). After 7 days, work-up and 
purification of the crude product by flash chromatography on silica gel [elution with hexane-
EtOAc (3:2)] afforded reddish-brown wax (0.24g), but 1H NMR analysis showed only a  trace 
amount of the desired product 2-acetyl-1-(5-hydroxy-2-nitrophenyl)-8-phenyl-4-aza-7-thia-1-
octene 68b; no purification was performed due to time constraints. 
 
Attempted preparation of 2-Acetyl-1-(5-chloro-2-nitrophenyl)-8-phenyl-4-aza-7-thia-1-
octene 68f 
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The general method was followed, using 3-chloromethyl-4-(5-chloro-2-nitrophenyl)but-3-en-
2-one 52f (0.81g, 3.0mmol), S-benzylcysteamine hydrochloride (1.2g, 5.9mmol) and 
triethylamine (0.83mL, 5.9mmol) in methanol (5mL). After 4 days, work-up and purification 
of the crude product by flash chromatography (elution with EtOAc) gave a reddish-brown 
____________________________________________________________________     Experimental_ 
86 
 
wax, but 1H NMR analysis of the wax failed to indicate the presence of the expected product 
68f. 
 
3.7 Reductive cyclization of Baylis-Hillman products to quinoline 
derivatives. 
 
2-Methyl-6,7-methylenedioxy-3-[(piperidin-1-yl)methyl]quinoline 69c 
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To a solution of 4-(4,5-methylenedioxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-
one 65c (0.2g, 0.6mmol) and ethanol (50mL), 10% Pd-C catalyst (24mg, 0.18mmol) was 
added and the reaction mixture was stirred under a hydrogen atmosphere for 1.5 hours. The 
reaction mixture was filtered and the filtrate concentrated in vacuo to afford, as a light yellow 
solid, 2-methyl-6,7-methylenedioxy-3-[(piperidin-1-yl)methyl]quinoline 69c (21mg, 12%), 
m.p. 201-203°C (Found M+1: 285.1649. Calc. for C17H21N2O2, MH+: 285.1603); δH 
(400MHz; CDCl3) 1.43 (2H, m, 14-CH2), 1.53 (4H, m, 13- and 15-CH2), 2.38 (4H, m, 12- and 
16-CH2), 2.70 (3H, s, CH3), 3.47 (2H, s, 11-CH2), 6.11 (2H, s, OCH2O), 7.00 (1H, s, 5-H), 
7.44 (1H, s, 4-H) and 8.10 (1H, s, 8-H); δC (100MHz; CDCl3) 14.4 (CH3), 24.3 (C-14), 25.9 
(C-13 and C-15), 54.5 (C-12 and C-16), 61.2 (C-11), 97.7 (C-8), 102.1 (OCH2O), 103.0 (C-5), 
124.6 (C-9), 125.5 (C-4), 130.1 (C-2), 138.0 (C-10), 145.8 (C-3), 148.6 (C-7) and 151.2 (C-6). 
 
Attempted preparation of 3-[(2-carbomethoxy-1-pyrrolidinyl)]-2-methyl-6,7-methylene-
dioxyquinoline 70c 
3
4
N
1
10
97
8
6
5 11
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O CH3
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The procedure described for the synthesis of 2-methyl-6,7-methylenedioxy-3-[(piperidin-1-
yl)methyl]quinoline 69c was followed, using 3-[(2-carbomethoxypyrrolidin-1-yl)methyl]-4-
(4,5-methylenedioxy-2-nitrophenyl)but-3-en-2-one 66c (0.2g, 0.5mmol), 10% Pd-C catalyst 
(18mg, 0.16mmol), ethanol (50mL) and hydrogen gas. The reaction was terminated after 
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stirring for 3 hours; the reaction mixture was filtered and the filtrate concentrated in vacuo to 
afford a brown oil (crude yield, 18%). The TLC analysis showed the presence of starting 
material and other components and the 1HNMR spectrum indicated the presence of a complex 
mixture, which could not be purified due to time constraints.  
 
Attempted preparation of 3-[(1-carbethoxy-2-hydroxyethylamino)methyl]-2-methyl-6,7-
methylenedioxyquinoline 71c 
9
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The procedure described for the synthesis of 3-[(1-carbethoxy-3-hydroxy-2-
propylamino)methyl]2-methyl-6,7-methylenedioxyquinoline 69c was followed, using 3-[(1-
carbethoxy-3-hydroxy-2-propylamino)methyl]-4-(4,5-methylenedioxy-2-nitrophenyl)but-3-
en-2-one 67c (0.2g, 0.5mmol), 10% Pd-C catalyst (28mg, 0.26mmol), ethanol (50mL) and 
hydrogen gas. The reaction was terminated after stirring for 1.5 hours; the reaction mixture 
was filtered and filtrate concentrated in vacuo to afford a reddish-brown oil (crude yield, 
23%). TLC analysis revealed multiple components and the 1HNMR spectrum indicated the 
presence of a complex mixture, which could not be purified due to the time constraints. 
 
3.8 Dehydration of Baylis-Hillman products to afford cinnamate esters  
 
Methyl (E)-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 72g  and methyl (Z)-
3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 73g 
2
3
NO2
4
57
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14
 
A mixture of methyl 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 58g 
(0.22g, 0.62mmol), EDC (2.7mL, 1.2mmol), copper(II) chloride (0.90mg, 0.06mmol) and dry 
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toluene (10mL) was boiled under reflux for 3 hours. The reaction was quenched with water 
and the resulting mixture extracted with ethyl acetate. The organic layer was washed 
sequentially with aqueous citric acid, aqueous sodium hydrogen carbonate and brine, and 
dried with anhydrous MgSO4. The EtOAc was removed in vacuo and the residue was 
chromatographed [preparative layer chromatography; elution with hexane-EtOAc (3:1)] to 
afford, as a yellow oil, a 1:2.7 mixture of the E and Z distereoisomers of methyl 3-(2-
nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 72g and 73g (95mg, 50%) (Found M+1: 
305.1501. Calc. for C16H21N2O4, MH+: 305.1501); νmax KBr/cm-1 1717 (C=O); δH (400MHz; 
CDCl3)# 1.41 (2H, m, 13-CH2), 1.55 (4H, m, 12- and 14-CH2), 2.48 (4H, m, 11- and 15-CH2), 
3.28 (2H, s, 10-CH2), 3.46 (3H, s, CH3), 2.22 (1H, d, J=7.6Hz, 9-H), 7.26 (1H, s, C=CH), 
7.42 (1H, t, J=7.8Hz, 7-H), 7.53 (1H, t, J=7.4Hz, 8-H), and 8.08 (1H, d, J=8Hz, 6-H); δC 
(100MHz; CDCl3) 24.2 (C-13), 26.0 (C-12 and C-14), 51.4 (CH3), 54.4 (C-11 and C-15), 61.3 
(C-10), 124.4 (C-6), 128.3 (C-7), 130.5 (C-9), 131.7 (C-2), 133.0 (C-8), 133.4 (C-5), 133.7 
(C=CH), 147.0 (C-4) and 168.0 (C=O). 
# NMR data cited for the major product. 
 
Methyl (E)-3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 72h and 
methyl (Z)-3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 73h 
2
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The procedure described for the synthesis of E and Z distereoisomers of methyl 3-(2-
nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 72g and 73g was followed,  using 
methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-[(piperdin-1-yl)methyl]propanoate 58h 
(0.20g, 0.57mmol), EDC (0.25mL, 1.7mmol), copper(II) chloride (23mg, 0.17mmol) and 
toluene (10mL). After work up, the crude product was purified by preparative layer 
chromatography [elution with hexane-EtOAc (3:1)] to afford, as a reddish-brown oil, a 1:7.2 
mixture of the E and Z distereoisomers of methyl 3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-
1-yl)methyl]prop-2-enoate 72h and 73h (30mg, 16%) (Found M+1: 335.1592. Calc. for 
C17H23N2O5, MH+: 335.1607); νmax KBr/cm-1 1728 (C=O); δH (400MHz; CDCl3)# 1.14 (2H, m, 
13-CH2), 1.53 (4H, m, 12- and 14-CH2), 2.39 (4H, m, 11- and 15-CH2), 3.32 (2H, s, 10-CH2), 
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3.57 (3H, s, CO2CH3), 3.39 (3H, s, Ar-OCH3), 6.79 (1H, s, 4-H), 6.83 (1H, d, J=7.6Hz, 9-H), 
8.94 (1H, d, J=8.4Hz, 7-H), and 7.39 (1H, t, J=8.0Hz, 8-H) ; δC (100MHz; CDCl3) 24.2 (C-
13), 25.9 (C-12 and C-14), 51.7 (CO2CH3), 54.7 (C-11 and C-15), 56.4 (Ar-OCH3), 61.7 (C-
10), 111.7 (C-7), 120.6 (C-9), 128.4 (C=CH), 130.7 (C-8), 131.0 (C-5),136.5 (C=CH), 140.0 
(C-4), 150.8 (C-6) and 168.1 (C=O). 
# NMR data cited for the major product. 
 
Methyl (E)-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(piperidin-1-yl-)methyl]prop-2-enoate 
72j and methyl (Z)-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(piperidin-1-yl-)methyl]prop-2-
enoate 73j 
2
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The procedure described for the synthesis of E and Z distereoisomers of methyl 3-(2-
nitrophenyl)-2-[(piperidin-1-yl)methyl]prop-2-enoate 72g and 73g was followed, using 
methyl 3-hydroxy-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propan-
oate 58j (0.20g, 0.56mmol), EDC (0.36mL, 1.6mmol), copper(II) chloride (15mg, 0.11mmol) 
and tolutene (10mL). After work up, the crude product was purified by preparative layer 
chromatography [elution with hexane-EtOAc (3:2)] to afford, as a light yellow oil,  a 1:3.9 
mixture of the E and Z distereoisomers of methyl 3-(4,5-methylenedioxy-2-nitrophenyl)-2-
[(piperidin-1-yl)methyl]prop-2-enoate 72j and 73j (15mg, 8%) (Found M+1: 349.1394. Calc. 
for C17H21N2O6, MH+: 349.1400); νmax KBr/cm-1 1719 (C=O); δH (400MHz; CDCl3)# 1.24 
(2H, m, 13-CH2), 1.57 (4H, m, 12- and 14-CH2), 2.50 (4H, m, 11- and 15-CH2), 3.30 (2H, s, 
10-CH2), 3.56 (3H, s, OCH3), 6.10 (2H, s, OCH2O), 6.62 (1H, s, 9-H), 7.22 (1H, s, C=CH) 
and 7.62 (1H, s, 6-CH); δC (100MHz; CDCl3) 25.9 (C-12 and C-14), 29.7 (C-13), 51.7 
(OCH3), 54.4 (C-11 and C-15), 61.3 (C-10), 103.1 (OCH2O), 105.2 (C-6), 109.2 (C-9), 130.3 
(C-5), 131.7 (C=CH), 135.0 (C=CH), 141.1 (C-4), 147.5 (C-8), 151.8 (C-7) and 167.9 (C=O). 
# NMR data cited for the major product. 
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